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ABSTRACT 
The Coronaviridae family consists of RNA viruses within the order Nidovirales. The family is 
classified into two genera, namely the corona- and toroviruses. Coronaviruses are enveloped, 
single stranded, positive sense RNA viruses with genomes ranging between 27-32kb in size. The 
5’ two-thirds of the genome encodes for the 1a/b polyprotein, while the 3’ one-third of the 
genome encodes for the structural proteins that mediate viral entry into the host cell. These 
structural proteins include the spike (S), envelope (E), membrane (M) and nucleocapsid (N) 
proteins. 
The nucleocapsid protein is expressed at high levels within an infected cell. Studies have shown 
that this protein plays a key regulatory role in different cellular pathways, including the 
inhibition of interferon production and the up-regulation of the AP1 signal transduction pathway, 
amongst others. Also, the N protein is vital in the formation of the ribonucleocapsid core by 
binding to the viral RNA during virion assembly. The focus of this study is the immune response 
in whole blood cultures to the presence of human coronavirus (HCoV) NL63 N protein. 
To characterise the stimulation of the immune activity against HCoV-NL63 N in blood 
cultures, the HCoV-NL63 N gene was expressed in a bacterial system. In this pilot study, GST-
tagged N constructs were then purified and used to treat whole blood cultures from three 
volunteers. ELISAs were used to measure the cytokine response in these treated whole blood 
cultures. Results showed that the nucleocapsid protein has an inflammatory response on whole 
blood cultures. These results have generated vital information in the potential function of the 
HCoV-NL63 N protein on the immune system. It is suffice to say that the HCoV-NL63 N 
protein is able to elicit an effective inflammatory response within the host cell. Future studies 
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into the cellular pathways affected by the HCoV-NL63 N protein will clarify its exact role in 
stimulating the host immune system.  
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1.1 Background 
Coronaviruses form a genus of the Coronaviridae family, with the name “Coronavirus” 
derived from the Latin word corona, meaning “crown”. When viewed under an electron 
microscope, a ring of small bulbous structures can be observed in the viral envelope under an 
electron microscope, and this gives the virus its characteristic appearance and its name (Lin, 
Feng et al. 2008; Smuts 2008; Woo, Huang et al. 2010). 
 
1.2 Discovery 
The history of research into human coronaviruses began in 1965 when Tyrrell and Bynoe 
found that a B814 virus could be passaged in human embryonic tracheal organ cultures. 
Although unable at the time to grow the virus in tissue culture, they would confirm B814’s 
presence by inoculating the medium intra-nasally into human volunteers, resulting in a 
significant number of the volunteers exhibiting common cold-like symptoms (Tyrrell and 
Bynoe 1965; Tyrrell and Bynoe 1966). 
 
At a later stage, Hamre and Procknow (1966) isolated a virus, obtained from medical 
students with the common cold, in tissue culture. This virus would later be named Human 
Coronavirus 229E (HCoV-229E). HCoV-229E, together with the B814 virus, was found to 
be ether sensitive, presumably requiring a lipid coat for infectivity to occur. By using a 
similar technique to Tyrell, McIntosh et al (1967) were able to recover several other ether 
sensitive viruses in organ cultures, the viruses were termed “OC” to indicate that they were 
grown in organ cultures. Within the same time frame Tyrrell and Bynoe found particles in the 
electron microscopy of organ cultures infected with the B814 virus to be similar in 
morphology to the infectious bronchitis virus of chickens, as well as to the mouse hepatitis 
virus (MHV) and the transmissible gastroenteritis virus of swine.  
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In 1975 these viruses were officially classified into a new genus, coronaviruses. 
Unfortunately, many clinical samples collected in the 1960s that proved to be positive for 
coronavirus-like particles were subsequently lost. In the three decades after the initial 
discovery, extensive research attention was paid almost exclusively to the study of Hamre’s 
HCoV-229E and McIntosh’s HCoV-OC43 viruses as they were the easiest to isolate and 
study at the time. Despite this, it soon became clear that there were other coronavirus strains 
circulating in human populations.  
 
1.3 Characteristics and taxonomy 
Collectively Coronaviridae, Arteriviridae and Roniviridae belong to the order Nidovirales as 
all the viruses in this order produce a 3′ co-terminal nested (Latin name nidus meaning 
“nest”) set of subgenomic mRNA′s during infection (Cavanagh, Brian et al. 1993; Woo, 
Huang et al. 2010). The Coronaviridae family is comprised of two genera, one being the 
actual Coronaviruses (CoV) and the other the Toroviruses. Originally Coronaviruses were 
classified according to the antigenic cross-reactivity into three antigenic groups. However, as 
the Coronavirus genomes were sequenced the original antigenic groups were converted into 
genetic groups, based on their nucleotide sequences (Liu and Sun 2008; Woo, Huang et al. 
2010). 
1.3.1 Group I 
Group I Coronaviruses contain three major viruses, HCoV-229E, Porcine Transmissible 
Gastroenteritis Virus (TGEV) and the Porcine Epidemic Diarrhoea Virus (PEDV), which are 
responsible for gastroenteritis and lower respiratory tract infections. TGEV in particular can 
have a severe impact on agriculture as gastroenteritis causes morbidity among pigs, and 
consequently high mortality rates among piglets (Enjuanes, Almazan et al. 2006). In March 
 
 
 
 
Chapter I 
 
4 
 
2004, a novel human pathogenic coronavirus isolated from a seven-month-old baby who had 
bronchiolitis and conjunctivitis designated HCoV-NL63 was discovered (van der Hoek, Pyrc 
et al. 2004). 
1.3.2 Group II 
Other pathogenic coronaviruses that belong to Group II are HCoV-OC43 and the recently 
discovered HCoV-HKU1, which are also responsible for the common cold in humans. 
HCoV-OC43 has also been associated with neurological diseases like multiple sclerosis 
(Edwards, Denis et al. 2000). Group II is also comprised of the Murine Hepatitis Virus 
(MHV), which causes bronchiolitis and infects the liver and brain of mice. MHV has 
previously been used as a model organism to study the pathogenesis of coronaviruses 
(Perlman and Ries 1987). 
 
1.3.3 Group III 
The avian Infectious Bronchitis Virus (IBV) and the Turkey Coronaviruses are the only 
members of Group III to date (Jia, Mondal et al. 2002). IBV is one of the main causes of 
economic loss within the poultry industry as it causes severe bronchiolitis and nephritis 
(Cavanagh, Brian et al. 1993). 
 
1.4 Emergence of SARS Coronavirus 
Given the enormous diversity of animal coronaviruses, it was not surprising when in 
November 2002 the cause of an outbreak of atypical pneumonia in the Guangdong province 
of South China was identified as a coronavirus, which soon after spread globally at a 
quantifiable speed (Ksiazek, Erdman et al. 2003; Peiris, Lai et al. 2003). The causative agent 
was identified as the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 
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(Drosten, Gunther et al. 2003; Peiris, Lai et al. 2003). During the 2002-2003 outbreaks, SARS 
infection was reported in 29 countries with a total of 8098 patients identified and 774 deaths 
recorded worldwide. A highly effective infection control response halted the SARS epidemic, and 
SARS-CoV is currently not in circulation (Pyrc, Berkhout et al. 2007).  
 
It is believed that SARS-CoV most likely originated from a wild animal reservoir and 
was  transmitted zoonotically to humans via infected Himalayan palm civets , which are sold 
as food in live-animal markets in China (Webster 2004; Cheng, Lau et al. 2007). Curiously , 
previous sero-epidemiology studies conducted among food market workers in SARS 
epidemic regions indicated that 40% of wild animal traders and 20% of those who slaughter 
animals were both seropositive for SARS-CoV, even though they were all asymptomatic 
(Guan, Zheng et al. 2003). These findings indicate that these individuals were previously 
exposed through their occupations to a SARS-like virus that had resulted in an asymptomatic 
infection (Drosten, Preiser et al. 2003).The SARS epidemic cast a light on the world of 
coronavirus research, and infused a level of attention that contributed to the detection and 
characterisation of previously unidentified respiratory viruses. Since 2003, five new human 
coronaviruses have been discovered, four of which are still circulating in the human 
population. 
 
Interestingly, coronaviruses as single-stranded RNA viruses have been shown to be fully 
equipped to adapt to rapidly changing ecological niches as they have a high substitution rate 
(Woo, Lau et al. 2009; Lau, Li et al. 2010). Also, homologous recombination has been 
observed in vitro and in vivo, implying that mutated or recombinant coronavirus variants can 
emerge anywhere at any time, possibly putting public health at risk as happened in case of 
SARS-CoV (Gibbs, Gibbs et al. 2004; Esposito, Bosis et al. 2006) . 
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1.5 HCoV-NL63  
 
1.5.1 Identification and Isolation 
 
In January 2003, a 7-month-old baby was admitted in Amsterdam hospital with coryza, 
conjunctivitis and fever, with a chest radiography depicting typical bronchiolitis features. A 
nasopharyngeal aspirate specimen was collected within five days, but all diagnostics yielded 
negative results. As a result, the clinical sample was inoculated onto monkey kidney cells and 
the cytopathic effect was observed. Initial PCR products showed that the sequence was in fact 
similar in sequence to other members of the Coronaviridae family (Brittain-Long, Nord et al. 
2008). 
 
A group led by Lia Van der Hoek of the University of Amsterdam developed a 
VIDISCA method (Figure 1), modified on a cDNA-amplified restriction length 
polymorphism (cDNA-AFLP), to identify the causative agent. This technique utilises viruses 
that have been isolated from cell culture supernatants of in vitro samples that display a 
cytopathic effect. Supernatants are treated with DNase to remove any mitochondrial and 
chromosomal DNA from degraded cells that interfere with the outcome. Subsequent use of 
frequently-cutting restriction enzymes were used to digest cDNA, allowing this method to be 
specific. In so doing, “sticky end” products can be ligated into anchors for amplification with 
selective primers.  
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Figure 1.1: VIDISCA technique used to identify the new HCoV-NL63 (van der Hoek, Pyrc et al. 
2004). VIDISCA utilizes the restriction of cDNA generated by RT-PCR of isolated viral RNA. 
As the restriction sites are known they, the digested fragments can be amplified with specific 
primers (van der Hoek, Pyrc et al. 2006) 
 
1.5.2 Seasonality and Prevalence of infection 
 
The first publications of HCoV-NL63 described several infected patients, indicating that 
infection by this coronavirus is not a rare event (van der Hoek, Pyrc et al. 2004). Patients 
infected with HCoV-NL63 suffer from both upper and lower respiratory tract infections, with 
symptoms being similar to that of HCoV-229E and HCoV-OC43 (Abdul-Rasool and Fielding 
2010). 
 
Previous literature has indicated that HCoV-OC43 and HCoV-229E are 
predominantly transmitted over the winter season in temperate climate countries (Hendley, 
 
 
 
 
Chapter I 
 
8 
 
Fishburne et al. 1972). Interestingly, HCoV-NL63 shows the same preference for the winter 
season, as studies conducted in Belgium, Australia, Japan, Canada, Germany and France have 
also indicated that the highest prevalence of this virus is within the winter season (Arden, 
Nissen et al. 2005; Bastien, Anderson et al. 2005; Ebihara, Endo et al. 2005; Moes, Vijgen et 
al. 2005; Vabret, Dina et al. 2008). Collectively these reports show that, although discovered 
in The Netherlands, HCoV-NL63 is not unique to this region but has a global distribution. In 
a Japanese study on 118 children under the age of 2 who were admitted into hospital with 
bronchiolitis, 3 were revealed to be positive for HCoV-NL63 infection (Ebihara, Endo et al. 
2005). A second study further revealed five HCoV-NL63 infections among 419 specimens 
collected from children with respiratory infections(Suzuki, Okamoto et al. 2005). 
 
HCoV-NL63 was also detected in Hong Kong in a prospective clinical study on 
children under the age of 18 presenting with acute respiratory tract infections. This study 
estimated that annually HCoV-NL63 infections account for the hospitalisation of more than 
200 children for every 100 000 under the age of 6 (Chiu, Chan et al. 2005; Lau, Woo et al. 
2006). A population study in Germany found that 49 out 919 children were positive for 
HCoV-NL63 (Forster, Ihorst et al. 2004; Konig, Konig et al. 2004; van der Hoek, Sure et al. 
2005). Studies conducted all indicate that the proportion of positive tests to be highest in the 
0-5 year age group. HCoV-NL63 infection is also frequently observed in patients who are 
immunocompromised due to HIV infection or chronic obstructive pulmonary disease 
(Fouchier, Hartwig et al. 2004; Arden, Nissen et al. 2005; Bastien, Anderson et al. 2005; 
Moes, Vijgen et al. 2005). 
 
HCoV-NL63 infections have been detected in 1.0-9.3% of cases of respiratory tract 
infections in children, 75% of them aged 2.5 to 3.5 years, the children found to be sero-
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positive for the virus (Dijkman, Jebbink et al. 2008; Fielding 2011). Coronaviruses 
epidemiology is poorly understood mainly because these viruses, including HCoV-NL63, are 
for a number of reasons, not routinely tested for. Firstly, the respiratory sites chosen for 
clinical sampling all produced different results obtained (Kleines, Scheithauer et al. 2007) 
and, secondly, the difference in the sensitivity of the various diagnostic assays routinely used 
(Fielding 2011). As a result, the development of sensitive and specific screening methods for 
human coronaviruses is important in understanding the epidemiology of these viruses. 
 
1.5.3Disease association 
 
1.5.3.1 Croup  
 
It has been shown that HCoV-NL63 contributes significantly to lower respiratory tract 
infections (LRTI). LRTI’s have been globally shown to be the leading cause of morbidity in 
children less than 5 years of age (van der Hoek, Sure et al. 2005; Kuypers, Martin et al. 2007; 
Dominguez, Robinson et al. 2009). Croup is a common manifestation of LRTI in children, 
and is assumed to be caused by a respiratory virus, with para-influenza and influenza A 
frequently implicated (Klig 2004). Croup is the inflammation of the trachea and is 
characterised by pharyngitis, sore throat and hoarseness of voice, and also produces a 
“barking cough” that usually worsens at night (van der Hoek, Sure et al. 2005; Han, Chung et 
al. 2007; Leung, Li et al. 2009; Sung, Lee et al. 2010). 
 
A prospective population-based study in Germany has reported an association 
between HCoV-NL63 and croup (Konig, Konig et al. 2004). It was found that 43% of the 
HCoV-NL63 positive patients without any secondary infection suffered from croup, whereas 
there was a prevalence of only 6% in HCoV-NL63 negative patients. The findings of this 
German study therefore suggest that a real link between HCov-NL63 and croup does exist 
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(van der Hoek, Sure et al. 2005; Weiss and Navas-Martin 2005; Sung, Lee et al. 2010). In 
fact, the possibility of developing croup is 6.6 times higher in HCoV-NL63 infected children, 
with the virus considered the second most common causative agent associated with the 
hospitalisation of children with croup (Fielding 2011) 
 
1.5.3.2 Kawasaki disease 
 
Of particular interest, HCoV-NL63 has also been associated with Kawasaki Disease (Esper, 
Shapiro et al. 2005). Kawasaki disease is an acute self-limiting vascular disease affecting 
children (Shimizu, Shike et al. 2005), and may result in aneurysms in the coronary arteries 
(Esper, Shapiro et al. 2005). It is the most common cause of acquired heart disease in 
children, although the aetiology remains unknown. 
 
Early epidemiological evidence and confirmation has shown that the respiratory 
syndrome precedes the symptoms of Kawasaki disease, thereby suggesting that a respiratory 
virus is the likely causative agent (Bell, Brink et al. 1981; McIntosh 2005). Kawasaki disease 
has been shown to have a seasonal pattern that is similar to a coronavirus infection, both of 
which peak in the winter season (Yanagawa, Nakamura et al. 1986). 
 
A study by Rowley et al has also shown that the Kawasaki disease will elicit a strong 
IgA response in the respiratory tract as well as other organs, indicating a possible entry of 
microbes through the respiratory tract (Rowley, Shulman et al. 2000). A case-controlled 
study conducted by Esper et al, investigated the association between Kawasaki disease and 
HCoV-NL63. Following PCR of samples collected, HCoV-NL63 was detected in 72 % of the 
patients that presented with Kawasaki disease. 4.5% of the control group tested positive for 
HCoV-NL63, thereby suggesting an association does in fact exist. This study was met with 
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scepticism as no corroborating studies have as yet confirmed these results (Belay, Erdman et 
al. 2005; Ebihara, Endo et al. 2005; Shimizu, Shike et al. 2005),  Ebihara and colleagues used 
this method of -PCR and found that only 1 out of the 48 samples tested from patients 
suffering with Kawasaki disease were positive for HCoV-NL63 (Ebihara, Endo et al. 2005). 
 
1.5.4 Co-infection 
 
HCoV-NL63 is often found in combination with a second respiratory virus, such as Influenza 
A (Chiu, Chan et al. 2005) respiratory syncytial virus, para-influenza-3 or human meta-
pneumovirus (A. Koetz 2006; Lambert, Allen et al. 2007; Kaplan, Dove et al. 2008). 
Although the viral load of HCoV-NL63 in co-infected patients is lower than a single 
infection with HCoV-NL63 (Debiaggi, Canducci et al. 2012), co-infected patients are more 
likely to be hospitalised, indicating the severity of this kind of infection (Abdul-Rasool and 
Fielding 2010). 
 
The decrease in viral load of HCoV-NL63 can be attributed to that fact that the innate 
immune response of the second respiratory virus inhibits the progression of HCoV-NL63, 
and also competes for the same target receptor in the respiratory tissues. It is also likely that 
HCoV-NL63 lowers the immune response, and in so doing creates a suitable environment for 
a subsequent infection with another virus. 
 
It has also been proposed that HCoV-NL63 promotes bacterial co-infection by 
increasing the adherence capabilities of Streptococcus pneumonia to human airway epithelial 
cells (Golda, Malek et al. 2011). It has believed that respiratory viruses like HCoV-NL63 
facilitate bacterial colonisation as they damage the epithelium cells found on the respiratory 
tract, creating a new binding site for the bacteria on the epithelial surface. 
1.5.5 Genome structure  
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A common feature of all coronaviruses is the 27-32kb positive sense single-stranded RNA 
genome, making it the biggest RNA virus. The genome is capped at the 5’ end and poly-
denylated at the 3’ end (Pyrc, Berkhout et al. 2007). The genome associated with HCoV-
NL63 is organised in the following gene order: 5’-replicase 1a-1b-S-ORF3-E-M-N-3’. 
HCoV-NL63 has three open reading frames with the ORF3 serving as an additional accessory 
protein between the S and E genes (Dijkman, Jebbink et al. 2008).  
 
The 5’ two-thirds of the genome that encodes for the 1a/b poly-protein has a stable 
nucleotide count, while the 3’ one-third of the genome encoding the structural proteins has an 
increased C-count, resulting in the GC ratio of HCv-NL63 being very low in comparison to 
other coronaviruses. The two ORF3’s 1a and 1b encode proteins necessary for RNA 
replication and make up two thirds of the genome, sharing an overlapping region of 40-60 
nucleotides. During translation of the 1a and 1b poly-proteins, there is a secondary RNA 
pseudo-knot structure that will initiate a ribosomal frame shift, triggering the ribosome to 
move one nucleotide upstream to encode for a completely new protein (Pyrc, Jebbink et al. 
2004; Sawicki, Sawicki et al. 2007). This frame shift is initiated when the elongating 
ribosome is stalled by a hepta-nucleotide sequence that is located upstream of the RNA 
pseudo-knot structure, leading to the completion of the poly-proteins 1a and 1b(Giedroc, 
Theimer et al. 2000; Namy, Moran et al. 2006; Sawicki, Sawicki et al. 2007). 
 
1.5.6 Transcription and Replication  
 
In order to express the proteins that are necessary for replication, the coronaviruses use a 
regulatory post-translation proteolytic process. The poly-proteins 1a and b within HCoV-
NL63 are cleaved by viral proteases to form a multi subunit protein complex that 
subsequently plays a role in replication and transcription. HCoV-NL63 has two proteinases in 
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the 5’region of the 1a poly-protein, the first being a papain-like proteinase that expresses the 
non-structural 3 gene (nsp 3) that will then catalytically cleave the 1a and b polyprotien at 3 
different locations. The second proteinase is expressed by the nsp5 gene, which contains 
serine-like domains that will further allow for the cleavage of a non-structural protein at the 
1a and b poly-protein. 
 
The 3’ end of the genome encodes for the structural proteins that participate in a 
budding process, thereby incorporating them into the viral particle. In replication, six mRNAs 
are produced, including a complete genomic RNA, and “nested” 5 sub-genomic RNA’s are 
produced (Pyrc, Berkhout et al. 2007). These 5 sub-genomic mRNAs each have an identical 
portion of 72 nucleotides and encode for the S, ORF3, E, M and N structural proteins 
necessary for viral assembly (Pyrc, Jebbink et al. 2004).  
 
HCoV-NL63 uses a discontinuous replication mechanism, which requires the RNA-
dependent RNA polymerase to pause after the transcription regulation sequence (TRS) of a 
specific gene is generated during negative strand synthesis. This delay allows the negative 
strand to be copied into positive strand mRNAs. The TRS is common to all sub-genomic 
mRNAs, with the exception of the E protein (Pyrc, Jebbink et al. 2004; Pyrc, Berkhout et al. 
2007; Sawicki, Sawicki et al. 2007). RNA expression levels of these sg-mRNA's increases in 
the 3’end direction in relation to their genomic position; as a result the sg-mRNA for the N 
protein is found to have the highest level of expression compared to the sg-mRNA of the S 
protein, which has the lowest. An exception does occur with the E proteins sg-mRNA, which 
is lower than expected. This is due to the fact that the E protein has a sub-optimal TRS core 
of AACUAUA instead of AACUAAA. This point mutation in the TRS core sequence may 
account for the low levels of expression of the E protein in coronaviruses. 
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1.5.7 Cell Tropism and receptor usage 
 
Infection of the host specific target cells occurs in coronaviruses via the binding of the S 
protein to the cellular receptors. The spike protein found in HCoV-NL63 is a class 1 fusion 
protein similar to that found in the Influenza virus HE protein and the HIV-1 envelope 
glycoprotein (van der Hoek, Pyrc et al. 2006). The viral replication strategy in coronaviruses 
begins with the binding of the spike protein to cellular receptors on the target cells. Initially it 
was believed that all group 1 coronaviruses, including the HCoV-229E, TGEV, PRCoV, 
feline and canine coronaviruses, all utilise the CD13 (aminopeptidase) receptor for infection 
in the target cell (Delmas, Gelfi et al. 1992; Yeager, Ashmun et al. 1992; Tresnan, Levis et al. 
1996). 
 
However, a group 1 coronavirus that is closely related to HCoV-229E the HCoV-
NL63 has been found to not use the CD13 receptor for cell entry (Hofmann, Pyrc et al. 2005). 
This impact of receptor specificity could be due to that fact that the HCoV-NL63 S protein 
has a unique 179 amino acid sequence at this N terminal that is not homologous to any other 
coronavirus proteins (Hofmann, Simmons et al. 2006). In addition HCo-V-NL63 and SARS-
CoV have both been shown to replicate in monkey kidney cells (Fouchier, Hartwig et al. 
2004; Hofmann and Pohlmann 2004), and although from different coronavirus groups, 
further infect Huh-7 cells: a human hepatocellular carcinoma cell line (Hofmann, Pyrc et al. 
2005) This analysis, coupled with receptor usage, has revealed that the HCoV-NL63-like 
SARS-CoV are the only coronaviruses that use the angiotensin-converting enzyme-II (ACE2) 
receptor to gain entry into the target cells (Li, Moore et al. 2003). This is puzzling as the 
HCoV-NL63 shares no amino acid identity with SARS-CoV. Hoffmann et al, showed that 
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despite a high homology between HCoV-NL63 and HCoV-229E, they form distinct surfaces 
at the C-terminal and thereby recognise the ACE 2 and CD13 receptors, respectively. 
 
1.6 Structural proteins 
 
1.6.1 Spike (S) protein 
 
The HCoV-NL63 S protein is a type 1 glycoprotein that is found on the viral surface, giving 
the virus its “crown-like” structure (Bosch, van der Zee et al. 2003). The S protein is 
produced in the Golgi bodies, resulting in the cleavage of the S protein into two S1 and S2 
subunits, each approximately 90kDa in size (Sturman and Holmes 1977). The N terminal of 
the S protein (S1) contains a receptor-binding domain located in the first 330 amino acids that 
is able to recognise the ACE2 receptor on the host target cell (Kubo, Yamada et al. 1994). 
The C terminal is found in the membrane region, together with two heptad regions (HR1 and 
HR2) and the fusion protein (van der Hoek, Pyrc et al. 2006). 
 
The primary function of the spike protein is to mediate the viral attachment to host-
specific cellular receptors, as well as facilitate viral entry into the host cell with antibodies, 
produced in vitro against the S protein having a neutralising effect (Pyrc, Bosch et al. 
2006)The S and M protein have also been shown to interact during the assembly of the virus. 
This will prevent the translocation of the S protein to the host cells membrane surface 
enabling the virus to evade the host immune system instead of being processed intracellularly 
(Opstelten, Raamsman et al. 1995). 
 
1.6.2 Envelope (E) protein 
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As mentioned previously, expression levels of the E protein remain low, making it a poorly 
characterised protein, this the result of the suboptimal variation of the TRS core sequence 
compared to other sub-genomic mRNA’s. The E protein is an integral membrane protein (Yu, 
Bi et al. 1994; Hurst, Kuo et al. 2005), playing a critical role in viral assembly (Vennema, 
Godeke et al. 1996; Hurst, Kuo et al. 2005; DeDiego, Alvarez et al. 2007) and virus 
replication (Yang, Xiong et al. 2005). 
 
Studies have shown that the co-expression of CoVs M and E protein in cell lines will 
result in the formation of a virus-like particle (Vennema, Godeke et al. 1996; Baudoux, 
Carrat et al. 1998; Corse and Machamer 2000; Huang, Yang et al. 2004; Bosch, de Haan et al. 
2005; DeDiego, Alvarez et al. 2007), thereby playing a vital role on viral morphology.  The E 
protein has also been shown to induce apoptosis (Weiss and Navas-Martin 2005) via the 
caspase-dependent pathway, as seen with the E protein of the Mouse Hepatitis Virus. In 
MHV is as been show that inhibition occurs via the over-expression of the anti-caspase 
protein Bcl2 (An, Chen et al. 1999; Yang, Xiong et al. 2005). 
 
1.6.3 Open Reading Frame 3 (ORF3) protein 
 
ORF3 is one of several accessory genes belonging to HCoV-NL63, which encodes the open 
reading frame-3 protein. The function of ORF3 protein in HCoV-NL63 is largely unknown; 
however, several homologues of the protein have been studied. The ORF3 protein of HCoV-
NL63 is homologous to ORF3 proteins of the other group 1b coronaviruses, namely PEDV, 
Bt-CoV/512/2005 (Tang, Zhang et al. 2006) and the ORF4 protein of HCoV-229E.(Dijkman, 
Jebbink et al. 2006). The ORF3 protein has also been found to play a role in the infectivity 
and pathogenicity of porcine epidemic diarrhoea virus (PEDV) (group 1b) and transmissible 
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gastroenteritis virus (TGEV) of group 1a (Kim, Hayes et al. 2000). Studies into the use of 
truncated forms of the ORF3 protein after serial passages in culture resulted in viruses with 
decreased pathogenicity (Woods 2001; Song, Yang et al. 2003). Piglets that were inoculated 
with the wild type PEDV developed severe diarrhoea (Andries and Pensaert 1981), while 
those inoculated with the highly cell-passaged form of the virus did not exhibit such 
symptoms. 
 
      TGEV, which is a group 1a coronavirus, as mentioned above, is associated with 
vomiting, diarrhoea, fever and even fatality in pigs. This is caused by infection and 
destruction of the epithelium of the small intestine. It was found that serially passaged TGEV 
led to a modified ORF3 gene that was smaller than the corresponding wild-type, which 
exhibited a decrease in virulence. Piglets inoculated with the modified TGEV had a lower 
morbidity upon exposure to the wild-type than the control group. Hence ORF3 provides a 
lucrative candidate for vaccine development. The deletion of accessory genes of feline 
infectious peritonitis virus (FIPV) and Murine Hepatitis Virus (MHV) have not been fatal to 
the virus in cell culture; it has, however, resulted in attenuation in vivo. (Herrewegh, 
Vennema et al. 1995; de Haan, Masters et al. 2002; Haijema, Volders et al. 2004). This is 
consistent with the observations of the group 1b ORF3 protein, but has not been found to be 
homologous with HCoV-NL63 ORF3. 
 
Extensive research has been done on the ORF3 protein of SARS, and although SARS 
ORF3a/b does not possess a high nucleotide homology with HCoV-NL63 ORF3, its location 
is consistent with the HCoV-NL63 homologues, i.e. between the S and E genes. (Tan, 
Barkham et al. 2005). The SARS ORF3 protein has been demonstrated to localise in both 
intracellular and plasma membranes (Song, Yang et al. 2003; Ito, Mossel et al. 2005; Yuan, 
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Li et al. 2005; Oostra, de Haan et al. 2006). Based on these findings, similarities between 
ORF3 of SARS and NL63 may be drawn 
 
1.6.4 Membrane (M) protein 
 
The M protein is a membrane glycoprotein that consists of three integral parts, a short N 
terminal, a triple membrane-spanning region and a cytoplasmic tail (Bond, Leibowitz et al. 
1979). The M protein is proposed to exist independently in the endoplasmic reticulum and the 
Golgi complex (Lim and Liu 2001). It has been shown to interact with the envelope protein in 
the budding compartment of the host cell. Also, the M protein in Group 2 coronaviruses has 
been shown to form a complex with both the hemagglutinin esterase and spike protein, 
respectively. Interaction with the nucleocapsid protein is believed to participate in RNA 
packaging into the virus (Escors, Ortego et al. 2001; Narayanan and Makino 2001; Kuo and 
Masters 2002; Bosch, de Haan et al. 2005). 
 
In the process of virion assembly, the M protein also interacts with the RNA- packaging 
signal to form the mature packaged virus particle (Narayanan, Chen et al. 2003). The 
interaction between the M protein and the S protein also seems to be an essential step in the 
assembly of the virus (He, Leeson et al. 2004; Bosch, de Haan et al. 2005). The uniqueness of 
the M protein is further highlighted by its ability to induce antibody production in hosts either 
during infection or during inoculation with attenuated viral vaccines. This takes place even 
though the greater part of the protein is buried within the viral membrane (Pulford and 
Britton 1991; Laude, Gelfi et al. 1992; Wesseling, Godeke et al. 1993; Vennema, Godeke et 
al. 1996). 
 
1.6.5 Nucleocapsid (N) protein 
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1.6.5.1 Structure and composition 
 
During the process of cell entry, virus particle assembly and release, the coronavirus 
nucleocapsid protein is produced abundantly within the infected target cell (Krokhin, Li et al. 
2003). The N protein’s primary function is the formation of the ribonucleocapsid helical core, 
which occurs when the N protein binds to a specific assembly signal on the viral RNA (He, 
Dobie et al. 2004; Surjit, Liu et al. 2004; Luo, Chen et al. 2005; Yu, Gustafson et al. 2005; 
Luo, Chen et al. 2006). Through this binding action with viral RNA dimers are formed as a 
result of SR-rich motifs. (Nelson, Stohlman et al. 2000; Fan, Ooi et al. 2005; Tan, Fang et al. 
2006; Chen, Chang et al. 2007). As virus assembly continues, the ribonucleocapsid core will 
bind to the C-terminal of the membrane glycoprotein inside the endoplasmic reticulum, 
which allows immature virions to develop (He, Leeson et al. 2004; Hurst, Koetzner et al. 
2009) and which are imperative for an effective viral replication cycle to occur. 
 
Other molecular aspects of the N protein include self-dimerisation (Surjit and Lal 
2008) RNA binding capabilities and the regulation of transcription, translation and replication 
(Baric, Nelson et al. 1988; Almazan, Galan et al. 2004; Verheije, Hagemeijer et al. 2010). 
Aside from being easily expressed in a bacterial system (Tan, Fang et al. 2006), the N protein 
is highly immunogenic and proves to be a suitable candidate for the detection of infection via 
the development of ELISA. The immunogenic responses of the N protein will be discussed in 
further detail in subsequent chapters. The N protein has also been shown to undertake post-
translation modifications like phosphorylation (Zakhartchouk, Viswanathan et al. 2005), 
acetylation (Dunker, Lawson et al. 2001) and sumolytion (Li, Xiao et al. 2005). 
 
1.6.5.2 Localisation  
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As mentioned in the preliminary section of this chapter, Coronaviruses and Arteriviruses are 
placed in the order Nidovorales (He, Dobie et al. 2004). The N proteins of these viruses have 
been shown to localise in the cytoplasm (Rowland, Chauhan et al. 2005; Surjit, Kumar et al. 
2005) nucleus and nucleolus (Hiscox, Wurm et al. 2001; Wurm, Chen et al. 2001; Timani, 
Liao et al. 2005; Reed, Dove et al. 2006). The potential function of the HCoV-NL63 N 
protein in regulating cell processes via its cellular localisation is currently unknown. Studies 
in other coronaviruses of the movement of the N proteins from the cytoplasm to the 
nucleoplasm have found that movement is dependant and initiated by nuclear localisation 
signals (NLS’s) that are found on the surface of the N protein The basic amino acids, lysine 
and arginine, enrich these NLSs, causing them to conform to three types of motifs: either 
monopartitespat4 and pat7, or a bipartite motif (Rowland, Chauhan et al. 2005). The 
movement of N proteins from the nucleus is mediated by nuclear export signals (NESs) (You, 
Dove et al. 2005). The passive transport of ions and molecules is carried out by these NESs, 
allowing for exportation between the cytoplasm and nucleoplasm to occur (Wurm, Chen et al. 
2001). 
 
1.6.5.3 Activation of IL-6 expression through NF-Κb transcription factor 
 
Upon examination of the lung lesions of patients suffering from an acute stage of SARS-
CoV, high serum levels of IL-6 were revealed (Zhang, Wu et al. 2007). This indicates that a 
high inflammatory response has been brought about by the presence of the SARS-CoV in the 
respiratory tract. IL-6 is a pleotrophic cytokine that provides the host with a defence 
mechanism against a foreign substance (Dosch, Mahajan et al. 2009). Aside from mounting 
an immunological inflammatory response, IL-6 also plays a crucial role in bone metabolism, 
neoplasia, ageing and anti-immune diseases (Akira, Taga et al. 1993; Papanicolaou, Wilder et 
al. 1998). 
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The activation of IL-6 within the host cell is dependent on the activity of many 
transcription factors like IRF-1, AP-1, C/EBP, SP1 and NF-Κb. In the presence of viruses, 
bacteria and mitogens in the cytoplasm, phosphorylation and degradation of an inhibitor to 
which the NF-Κb transcription factor is bound will allow the NF-Κb to translocate to the 
nucleus. To understand the molecular mechanisms involved in an inflammatory response, 
Zhang et al, (2007) have shown that the N protein stimulates the expression of IL-6. They 
further investigated if the NF-Κb transcription factors, along with the N protein, are 
necessary for the expression of IL-6. Other studies also revealed that NF-Κb is necessary for 
the N protein to activate IL-6 expression, with both NF-Κb and the N proteins having a 
synergistic effect (Zhang, Wu et al. 2007). 
 
1.6.5.4 Inhibition of IFN- 
 
The production of a type 1 interferon within the host cell is important in the innate immune 
response to a viral pathogen (Cheung, Poon et al. 2005; Frieman, Heise et al. 2008). The 
toll-like and RIG-1 receptor dependent pathways are employed to activate Type 1 
interferons, which takes place via the detection of ds or ss RNA viral genome during 
replication or the lysis of infected cells. After interferon synthesis, it is released from the 
cells and binds to a receptor that will initiate the JAK-STAT pathway, and express 
interferon-stimulating genes that will allow the host system to combat infection. (Kopecky-
Bromberg, Martinez-Sobrido et al. 2007). SARS-CoV infection does not produce an 
interferon response, indicating that it has developed a mechanism to overcome this. Studies 
have shown that the ORF3b, ORF6, N (Frieman, Heise et al. 2008) and M (Siu, Kok et al. 
2009) proteins of the SARS-CoV can suppress interferon responses.  
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1.6.5.5 Activation of the AP1 pathway 
 
As seen with many other proteins, the nucleocapsid protein has also been shown to enter the 
nucleolus during the interphase of the cell cycle (Hiscox, Wurm et al. 2001). This may be a 
result of its phosphorylation after translation has occurred (Smith and Kotwal 2002; Reed, 
Howell et al. 2007). This movement allows the N protein to interact with the signal 
transduction pathways and thus evade the host immune system.  
 
An example of this interaction was observed in the activator AP1 pathway, which is involved 
in the regulation of cell proliferation, differentiation and apoptosis (Shaulian and Karin 
2002). There are two molecules homodimers and heterodimers that make up the AP-1 signal 
transduction pathway, and a study by He and colleagues has proposed that, due to these 
dimers, the AP-1 signal transduction pathway is activated by the SARS-CoV N protein in a 
dose-dependent manner (He, Leeson et al. 2003). 
 
1.7 Aim of this study 
 
1. RT-PCR amplification of HCoV-NL63 genes encoding for the structural proteins M, 
E, and the accessory ORF3 protein from viral RNA. 
2. Cloning of these amplified products into pFLEXI vector to allow expression into a 
bacterial system. 
3. Cloning of amplification products into a pGEX-4T-2 vector for bacterial expression. 
4. Expression and purification of these structural proteins, including previously cloned 
and verified SARS-N and HCoV-NL63 N proteins. 
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Studies have indicated that the SARS-N protein will elicit an immune response in 
various in vitro systems, causing the release of inflammatory cytokines and inhibiting 
interferon production. As a result, is it plausible to infer that the HCoV-NL63 protein 
will cause a similar response? Therefore our hypothesis is that the inflammatory 
cytokine IL-6 is stimulated by these recombinant viral proteins (SARS-N and HCoV-
NL63 N) in whole blood cell (WBC) culture systems. Our alternate hypothesis is that 
these viral proteins do not elicit an immune response.  
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2.1. ABSTRACT 
 
The M, E, ORF3 and N structural proteins of HCoV-NL63 level of toxicity remains a mystery. 
However based on the cytotoxicity exhibited by other coronaviruses, it is necessary for the 
molecular and proteomic characterisation of these proteins to be determined. In this study we 
detail the cloning and expression of the structural proteins of HCoV-NL63.  
Molecular characterisation was initiated by the reverse transcription of NL63 RNA to generate 
cDNA. Upon amplification, amplified genes were ligated into a pGEM shuttle vector before 
transformation into E. coli (JM109) cells. After confirmation through sequencing, these pGEM -
gene constructs where then extracted from the cell via alkaline lysis and restriction enzyme 
digested. The restriction enzyme digest used two rare enzymes; Sgf1 and Pme1 to produce 
“sticky ends”, which then allowed the genes to be further ligated into a bacterial expression 
vector-pFLEXI. KRX E. coli served as the protein expression model for these gene-vector 
constructs. Thereafter, protein expression was analysed via Western blot against the GST fusion 
proteins. Optimisation of expression using various parameters such as temperature control, auto-
induction, and solubilisation resulted in inadequate expression of the HCoV-NL63 M, E, and 
ORF3 proteins, with only N protein being expressed successfully. These results indicate that the 
low level of toxic protein expression in the lag and growth phase may be due to an unstable 
promoter sequence seen on the pFLEXI vector system. 
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2.2. INTRODUCTION 
Since the advent of recombinant DNA technology, there has been a great expansion in the study 
of the many different proteins found in living organisms. As a result, the expression and 
purification of proteins has become a fundamental part of many aspects of research. However, 
the success of the expression of recombinant proteins often remains frustratingly elusive because 
of the complex structure of proteins in a host system.  
There are numerous systems available for protein production, but the use of the Gram-negative 
Escherichia coli bacterium is preferred for its ability to grow rapidly, the low cost of culturing 
and the availability of a large number of cloning plasmids (Baneyx 1999). Bacterial expression 
has also been shown to be beneficial in the expression of a heteromultimeric protein like the α 
and β subunits of human haemoglobin to form a fully functional tetrameric structure (Hoffman, 
Looker et al. 1990) Although a relatively easy-to-use system, the over-expression of 
heterologous proteins in E. coli often yields inadequate soluble proteins (Baneyx 1999; Edwards, 
Arrowsmith et al. 2000; Hammarstrom, Hellgren et al. 2002). To overcome this limitation, the 
optimisation of expression conditions such as temperature, growth media, induction parameters, 
promoter and E. coli expression strains is necessary (Braun, Hu et al. 2002) Once proteins have 
been expressed, the next step is to purify those proteins. This is achieved via the use of an 
affinity tag. Common affinity tags include GST, HIS and MBP, which enhance protein 
solubility. Although the addition of a fusion tag onto a protein can improve expression, the tag 
has also been shown to interfere with protein structure and function (Kapust and Waugh 1999; 
Wu and Filutowicz 1999; Bucher, Evdokimov et al. 2002). It is thus advisable to remove the tag 
after purification.  
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This chapter reports the cloning and expression of the HCoV-NL63 structural proteins: E, M, 
ORF3, and N proteins. Deletion mutants of the hydrophilic regions of the M and ORF3 have also 
been generated to increase the solubility of the fusion proteins, which would allow for 
subsequent purification. The N protein and truncated clones were previously cloned and 
sequenced and included in expression studies to allow for further immunological studies in the 
proceeding chapter. 
The expression of all the above-mentioned clones occurred downstream from the glutathione-S-
transfer (GST) fusion protein, which was used to allow for detection and purification. The GST 
tag can be used for protein expression as it allows for by the use of a T7 RNA polymerase 
promoter found in the pFLEXI vector system. To carry out expression, the use of a suitable 
bacterial strain that expresses the T7 RNA polymerase is required. The bacterial strain used here 
was K12 E. coli derivative KRX. KRX has high transformation efficiency because of the absence 
of proteases and nucleases. Good protein expression is possible as the vector contains a 
chromosomal copy of the T7 RNA polymerase gene that has a rhamnose promoter, which helps 
control the expression of recombinant proteins. This promoter is activated via the addition of 
rhamnose to the medium, thus providing precise control of T7 RNA polymerase levels that, in 
turn, control the recombinant protein expression. Rhamnose induces the activation of RhaR, 
which in turn will induce the production of active RhaS, which will bind to the rhamnose 
activating transcription from RhaBAD. The isomerase (RhaA), kinase (RhaB) and aldolase 
(RhaD) are deleted and replaced with the T7 RNA polymerase in KRX. Rhamnose is not 
metabolised by the cell and is not consumed during growth, but is merely required for efficient 
expression (Hartnett, Gracyalny et al. 2006). 
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In this study, the expression of HCoV-NL63 E, M, ORF3, MΔN and ORFΔN could not be 
detected in either the soluble or insoluble fractions, even though the GST tag is known to 
increase protein solubility and expression. Several factors could possibly have contributed to this 
occurrence, viz cloning errors, vector toxicity and lethality of the Barnase gene, and protein 
degradation by bacterial proteases. Plasmids can be lost at low frequency during cell division. 
This loss can, however, be offset if the ligated genes it carried are toxic to the cell (Baneyx 
1999). Sequencing prior to expression and the insertion of the AmpR gene for ampicillin 
resistance prevented the growth of plasmid-free cells, and in so doing ruling out the possibility of 
cloning errors. 
 
2.3. MATERIALS AND METHODS 
2.3.1 Reagents  
HCoV-NL63 RNA was a kind gift from Prof L. van der Hoek, of The Netherlands. A clinical 
sample was obtained and the RNA was extracted from the fifth passage of an Amsterdam 1 viral 
strain. The kits used for SDS gel and Western blot preparation were obtained from Sigma 
Aldrich. Glycerol stocks of GST-tagged nucleocapsid constructs, cloned into pFlexi vector, were 
kindly provided by Mr M. Berry (Department of Medical Biosciences, University of the Western 
Cape). Recombinant constructs included SARS-CoV N, HCoV-NL63-N, and N and C terminus 
deletion mutants of HCoV-NL63 N. For the purpose of this and the following chapter, the constructs 
were named SARS-N, N1, N2 and N3, respectively (Table 2.1). 
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Table 2.1: Constructs used for expression in this chapter 
Constructs Name Description of construct a.a. position 
SARS-N Full-length SARS-CoV N gene 1-423  
N1 HCoV-NL63 full length  1-378  
N2 N-terminal half of the HCoV-NL63 N  1-189  
N3 C-terminal half of the HCoV-NL63 N  191-378  
 
2.3.2 Bacterial strains and plasmids 
Bacterial strains used in this study were all obtained from Promega. These include the KRX, 
BL21 and JM109 E. coli-competent cells. KRX is a K12 derivative that can be used with a 
pFLEXI expression vector. On the other hand, a λ (DE3) pLysS strain was used with a pGEX-
4T-2 expression vector to express the E, M and N HCoV-NL63 structural proteins for further 
studies (Appendix III). Both the pFLEXI and pGEX-4T-2 expression vectors are under the 
control of a T7 promoter. The pGEM-T-easy vector system was included to allow for the 
confirmation of the gene of interest because of its convenience for cloning PCR products. Initial 
transformation with the pGEM vector was carried out using the JM109 competent cells. KRX 
competent cells were used for optimisation and the final expression of the recombinant proteins. 
The pFLEXI vector was used due to its unique ability to express fusion and native proteins to 
allow for further studies into protein function and structure. 
2.3.3 Generation of recombinant plasmid vectors 
2.3.3.1 Reverse Transcription  
 
 
 
 
  Cloning and Expression of HCoV-NL63 proteins 
 
45 
 
1
st
 strand cDNA was generated from HCoV-NL63 RNA, using the Reverse Transcription System 
(Promega) according to the manufacturer’s instruction. cDNA was transcribed from HCoV-
NL63 RNA using 25 mM MgCl
2
, Reverse Transcription 10x buffer, 10 mM dNTP mix, RNAsin 
(Promega), 25 U/μl Reverse transcriptase, Oligo dT Primer (0.5 μg/μl), test RNA and nuclease-
free water to make up a final volume of 20.0 μl in a sterile microcentrifuge. The control was a 
water-blank with all the reagents mentioned above except RNA, which was replaced by 
nuclease-free water, in order to ascertain the purity of the reagents. The mixture was made while 
carefully working on ice. The transcription conditions were set at 42ºC for 60 minutes, 95ºC for 
5 minutes and 0ºC for 5 minutes. Thereafter the product was stored at -4ºC until required. 
2.3.3.2 Primer design 
The HCoV-NL63 E, M, ORF3, ORF3ΔN and MΔN nucleotide sequences was retrieved from 
NCBI. Using the obtained nucleotide sequence as a template, the forward and reverse primers 
were designed using Promega primer design tools. For ligation into the Flexi™ protein 
expression vector, a SgfI (5´-GCGATCGC-3´) restriction-site was incorporated into the forward 
primer and a PmeI (5´-GTTTAAAC-3´) restriction site was incorporated into the reverse primer. 
An additional C residue was appended upstream of the ATG in the forward sequence to prevent a 
frameshift in the reading frame. These primers were used as 100 ρ.mole/μl stock solutions and 
their nucleotide sequences are shown in table 2.2 
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Table 2.2: Sequences specific forward and reverse primers for each gene used in PCR amplification 
Primer Name Sequence 
ORF3-Flexi. Fw GCGAATTCAATGCCTTTTGGTGGCCTATTC 
ORF3-Flexi. Rw GCTCTAGATCAATTAATCGAAGGAACATGC 
M-Flexi. Fw TGCGGCGATCGCCATGACTTTGGCGCCGTGTTAAA 
M-Flexi Rw  TGTGGTTTAAACTTAGATTAAATGAAGCAACTTCTCA 
E-Flexi. Fw GCGCGCGATCGCCATGTTCCTTCGATTAATTG 
E-Flexi. Rw GCGCGTTTAAACTTAGACATTTAGTACTTCAGC 
ORF3ΔN. Fw AGCAGCGATCGCCATGTACTCATTCGTTTCGGA 
ORF3ΔN. Rw 
MΔN. Fw 
MΔN. Rw 
TTGTGTTAAACTTAGACCAGAAGATCAGGAA 
AGCAGCGATCGCCATGTACTCATTCGTTTCGGA  
TTGTGTTAAACTTAGACCAGAAGATCAGGAA  
Bold: - Sgf1 cut site (Fw); Pme1 cut site (Rw), underlined and italics:-stop/start codon 
 
2.3.3.3 Gene amplification-PCR 
The PCR reaction was set-up in a final volume of 25μl with 0.2mM dNTP mix, 1.5 mM MgCl2, 
4μM forward and reverse primers, 5μl 5x green GoTaq Flexi buffer, 0.5 μl 5u/μl GoTaq 
polymerase and 2μl cDNA template. 
Of the 10 primers the lowest Tm was 64.68°C for the NL63 N2 reverse primer and, therefore, an 
annealing temperature of 60°C was chosen to ensure high specificity of binding of base pairs to 
the template strand. PCR amplification was therefore run under the following conditions: 95°C 
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for 3 min followed by 30 cycles of 95°C for 1 min, 60°C for 1 min and 72°C for 2min. The final 
elongation was run for 15 min at 72°C. 
2.3.3.4 Agarose gel electrophoresis 
The PCR product was diluted in a ratio of 1:5 with 6 x Blue/Orange loading dye (0.4% (v/v) 
orange G, 0.03% (v/v) bromophenol blue, 0.03% (v/v) xylene cyanol FF, 15%(v/v) Ficoll® 400, 
10 mM Tris-HCl (pH 7.5) and 50 mM EDTA (pH 8.0). The amplification reactions were run on 
a 1% (w/v) agarose gel, containing 0.001% (v/v) ethidium bromide, by electrophoresis in TBE 
buffer (89 mM tris (hydroxymethyl) aminomethane, 0.089 mM boric acid, 2 mM EDTA (pH 8)). 
The gel was run at 90 volts, 2 amperes for a period of approximately 1 hour. The size of the 
DNA fragment of interest was determined according to the DNA migration pattern in an agarose 
gel compared to that of a pre-determined DNA molecular weight marker. When the PCR 
fragment was visualised under the high frequency ultraviolet (UV) light, exposure to UV light 
was minimised to avoid damage to the DNA. 
2.3.3.5 Purification of PCR products 
The PCR product to be ligated was gel purified by means of the Wizard® PCR Preps DNA 
purification systems (Promega) according to the manufacturer′s specifications. Briefly, the bands 
to be cloned were excised from the agarose gel by means of a clean scalpel and razor blade. A 
weighed gel slice was completely dissolved by incubation at 50ºC for 10 min, with occasional 
vortexing in the presence of a membrane binding solution (4.5 M guanidine isothiocyanate and 
0.5 M potassium acetate) at a ratio of 1:1. The gel mixture was then transferred into an SV 
minicolumn, where it was washed with membrane wash solution (10 mM potassium acetate, 
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80% (v/v) ethanol and 16.7 μM EDTA). The DNA was finally eluted with nuclease-free water 
into a sterile micro-centrifuge tube. 
2.3.4 Cloning and verification of amplified products  
2.3.4.1 Ligation into pGEM and JM109transformation 
A ligation reaction was then performed using the Promega pGEM T-easy vector system and the 
purified PCR product from above. The reaction mixture was set up using 2 x ligation buffer, 
pGEM vector (50ng/μl), T4 DNA ligase (3U/μl) and 3.5 μl of PCR product. The positive control 
used here had the control insert DNA (Promega) in place of PCR product, and the negative 
control had nuclease-free water replacing the DNA. Ligation was done overnight at 4ºC. 
Transformation into E. coli (JM109) competent cells was performed using the pGEM T-easy 
system as per manufacturer’s instructions (Promega). 4 μl of ligation product, including the 
controls, was dispensed into sterile 1.5 ml microcentrifuge tubes and placed on ice. Competent 
cells were thawed on ice for 5 minutes and 50 μl dispensed into each reaction tube. After gently 
flicking the tube to mix the contents, the tube was placed on ice for 20 minutes. The cells were 
then heat-shocked by placing the tubes in a dry heating block at 42°C for 45 seconds and 
immediately returned to ice for a further 2 minutes. 950 µl sterile LB broth (1% bacto-tryptone, 
0.5% bacto -yeast extract and 0.5% NaCl) was preheated to 37°C  and then added to each tube 
and incubated at 37°C for 90 minutes on a shaker at approximately 150rpm. 
LB agar plates were prepared with 1% Bacto – Tryptone, 0.5% Bacto – Yeast extract, 0.5% NaCl 
and 1.5% agar. This agar mixture was autoclaved and upon cooling Ampicillin was added at 1 µl 
per ml before pouring the plates and allowing them to set on a flat surface. Working aseptically 
to avoid contamination, and with the aid of a hockey stick, 100 μl of transformed sample was   
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spread onto duplicate LB agar plates containing 100 μl IPTG (100 mM), 20 μl Xgal (50mg/M) 
and 10 μl ampicillin (100mg/M). The positive and negative controls from the transformation 
reactions were used, together with a plate for competent cells only, to verify the effectiveness of 
the ampicillin. Plates were then incubated overnight at 37°C. Thereafter plates were sealed with 
parafilm and placed in the fridge for approximately 8 hours to intensify the colour of the blue 
colonies to distinguish between blue (untransformed) and white (transformed) colonies. Eight 
white colonies were inoculated into 8 tubes, each containing 10 ml of LB broth and 10 µl of 
ampicillin, and the culture was  grown overnight at 37ºC with agitation. 
2.3.4.2 Colony PCR 
In addition to the above-mentioned grow-up, a colony PCR was carried out to verify that the 
colony picked for culturing does in fact contain the inserts (transformed). The colony PCR 
mixture was made up using 5 μl dNTP mix (10mM); 1.5 μl MgCl
2
, 2.0μl 10X buffer, 1.0 μl 
forward and reverse primers (100 μM), 0.5μl Taq Polymerase and 3.5μl nuclease-free water to 
make up a final volume of 10μl of sample. The cDNA was obtained by briefly inserting a sterile 
pipette that was used to pick the colony into the PCR mixture. The samples were then placed in a 
thermocycler under conditions specific for each gene. The reaction was run for 30 cycles with a 
final extension temperature was set at 72
 
ºC for 15 minutes, and thereafter a soak temperature of 
4ºC. After which the samples were run on a 1% agarose gel to verify which of the colonies 
contain the correct inserts of gene. Upon verification via electrophoresis, the overnight cultures 
that contained the inserts were then mini-prepped to extract the DNA for further use. 
2.3.4.3 Extraction of plasmid DNA 
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Plasmid DNA was isolated from the transformed cells using a Wizard® plus SV minipreps DNA 
purification system. Briefly, a single bacterial colony that was confirmed to contain the amplicon 
by colony PCR was inoculated into 10 ml of LB medium containing antibiotics, and incubated 
overnight at 37ºC. The culture was pelleted for 5 minutes and then immediately resuspended in 
250 μl of cell re-suspension solution (50 mM Tris-HCl, 10 mM EDTA). This was mixed with 
another 250 μl of cell lysis solution (1% (w/v) SDS, 0.2 M NaOH) and then mixed by inverting. 
To this mixture, 10 μl of alkaline protease solution was added, mixed and then incubated for 5 
minutes at room temperature. Following incubation, the sample was mixed with 350 μl of 
neutralizing solution mM potassium acetate, 8.3 mM Tris-HCl, 40 μM EDTA), inverted and then 
centrifuged at top speed (13 000 rpm) at room temperature for 10 minutes. Once the cleared 
lysate was obtained, the lysate was decanted into a spin column and then centrifuged for 1 
minute at top speed. The flow-through was discarded and the column reinserted into the 
collection tube. 750 μl of wash solution was added and the sample was centrifuged at top speed 
for 1 minute. The spin column was then washed with 250 μl wash solution and centrifuged for 2 
minutes. The plasmid DNA was eluted by transferring the spin column into a sterile centrifuge 
tube, followed by addition of 30 μl of nuclease free water to the spin column. The latter was 
centrifuged at top speed for 1 minute and the DNA stored at -20°C. 
2.3.4.4 Sequencing 
Since PCR was used to create the original insert, the sequence of the protein coding region in the 
initial clone was verified by automated DNA sequencing. Cycle sequencing was performed at 
Inqaba Biotech. The clone corresponding to the initial nucleotide sequence (NCBI) was selected 
for further experimentation. Following in silico analysis, the construct was digested with pFlexi 
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restriction enzymes (Sgf1 and Pme1) for ligation into a pFlexi vector that has been digested with 
the same restriction enzymes. 
2.3.4.5 Restriction endonuclease digest  
4μl of DNA from the mini preps mentioned above was cut with 1μl of Sgf1 and Pme1 restriction 
enzymes. 4 μl of 5X flexi digest buffer and 11 μl of nuclease-free water were micro-centrifuged, 
and then placed in a dry heating block for 3 hours at 37°C. Thereafter the temperature was 
changed to 65°C to inactivate the restriction enzymes. The entire product of each sample was 
then loaded onto a 1% agarose gel to allow for the purification of the product of interest. The gel 
was purified using the Wizard® SV gel and PCR cleanup system (Promega), as per protocol.  
2.3.4.6 KRX transformation and ligation into pFLEXI vector system 
After cutting the DNA with the Sgf1 and Pme1 enzymes, ‘sticky ends’ are produced which can 
then be ligated into compatible sites of pFLEXI (pFN2a-GST ) bacterial expression vectors using 
the pFLEXI  vector systems as per protocol (Promega). Ligation into the pFLEXI vector was 
done using 11 μl DNA, 5μl Flexi vectors (GST), 2μl of 10 x ligation buffer and 2μl T4 DNA 
ligase (3 U/μl) in a final volume of 20 μl. Ligation was done overnight at 4ºC. 
Transformation into KRX competent cells >10
6
 cfu/ μg (Promega) was done per protocol using 
50μl aliquots of competent cells. The KRX competent cells were thawed on ice for 5 minutes. 
5μl of ligation product was dispensed into the 50μl aliquot of competent cells, and after gently 
flicking the tubes were returned to ice for 20 minutes. The cells were then heat shocked on a dry 
heating block at exactly 42°C for 15 seconds and, without shaking, immediately returned to ice 
for another 2 minutes. 450 μl sterile LB broth (1% bacto-tryptone, 0.5% bacto -yeast extract and 
0.5% NaCl) at room temperature was added to each tube and incubated at 37°C for 90 minutes 
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on a shaker at approximately 150rpm. 100 μl of transformed samples containing the GST tagged 
construct were spread-plated onto duplicate LB agar plates containing 10μl of ampicillin 
(100mg/M). 
 
Negative controls were set up by plating the viral constructs on kanamycin LB agar plates. Plates 
were then incubated overnight at 37ºC, together with untransformed E.coli cells, cells 
transformed with control DNA and ligation controls to check efficiency of ligation and reagents. 
Ten colonies were inoculated into 10 greiner tubes, each containing 10 ml of LB broth and 10 μl 
ampicillin for the GST tagged proteins. The cultures were grown overnight at 37ºC with agitation 
by placing them on a shaker.  
2.3.5 Expression studies  
2.3.5.1 Autoinduction 
The autoinduction protocol as described by Schagat et al. (2008) utilises glucose and rhamnose 
to tightly control the T7 RNA polymerase gene via a rhamnose promoter (rhaPBAD), which has 
been shown to be inhibited by the metabolites of glucose via a cyclic AMP (cAMP) 
pathway(Holcroft and Egan 2000). Glucose may therefore be used to inhibit pre-induction 
protein expression, where rhamnose will induce protein expression, but only once the glucose is 
completely metabolised from the culture medium. 
We utilised an early autoinduction protocol where glycerol stocks of HCoV-NL63 M, ORF3, E, 
ORF3ΔN and MΔN in the pFLEXI vector where inoculated into a starter culture of 10ml LB 
medium and incubated at 37°C for 14 hours with shaking at 180rpm. Starter cultures were 
diluted 1:100 into a LB medium supplemented with 0.05% (w/v) glucose and 0.1% (w/v) 
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rhamnose, and incubated at 37°C with shaking at 180rpm. Samples of 50ml were taken at 8 and 
24 hours and harvested by centrifugation at 6000rpm for 15 minutes at 4°C to prevent protein 
degradation. Dry cell pellet was frozen at -80°C until further use. We were unable to detect any 
protein expression and therefore chose to modify the expression protocols as follows. 
2.3.5.2 Induction at specific OD600 reading with fermentation at 37°C 
Glycerol stocks were inoculated into 10ml of LB medium and incubated for 14 hours at 37°C 
with shaking at 180rpm. Starter cultures were diluted 1:100 into 100ml LB medium and 
incubated for approximately 4 hours, at which time OD600 readings were taken. Once the culture 
reached an OD600 of 0.3-0.4, expression was induced by the addition of 0.1% (w/v) rhamnose. 
Cultures were incubated as previously described for 24 hours when cells were harvested by 
centrifugation at 6000rpm for 15 minutes. Expression was undetectable, and so we chose to 
further modify the expression protocol by reducing the fermentation temperature to 25°C. 
2.3.5.3 Induction at specific OD600 reading with fermentation at 25°C 
The previous method was maintained until after induction of expression where the fermentation 
temperature was reduced to 25°C. Low yields of expressed proteins may indicate toxicity to the 
cell by the heterologous protein, and decreasing the fermentation temperature will as a result 
slow the initial expression of the protein, allowing the cell to acclimatise and in so doing increase 
final yields. We, however, were not able to detect any protein expression and therefore returned 
all fermentation temperatures to 37°C. 
2.3.5.4 Time course expression 
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Expression protocols described above were maintained where starter cultures were inoculated 
into 1500ml LB medium. Samples of 200ml were then taken, at 4, 8, 12, 16, 20 and 24 hours 
post-induction to determine at which point expression is at its highest. Protein catabolism was 
not detected at these various time points, and thus large-scale expression was adopted. 
2.3.5.5 Large-scale expression 
Due to the low levels of protein expression and a reduction in cell density, a large-scale culture 
was deemed necessary to obtain an ideal concentration for protein purification. The expression 
protocols described previously was maintained where starter cultures were inoculated in 1500ml 
LB medium with the addition of 1mM IPTG on induction. A small level of protein expression 
was detected for the M protein (Appendix II); however, upon repetition of this protocol 
expression was no longer detected. 
 
2.3.6. Protein Analysis 
2.3.6.1 Protein extraction and Preparation of Cell Lysates 
Following centrifugation, cell pellets were resuspended by vortexing in 2ml/g lysis buffer 
containing 1% (v/v) TritonX, 150mM NaCl, 10mM Tris(hydroxymethyl)-amino-methane (Tris), 
5mM EDTA and a protease inhibitor cocktail. Table 2.3 describes the function of all constituents 
in the lysis buffer. Cells were subsequently lysed by sonication in an ice bath to prevent protein 
degradation. All subsequent work was done on ice or at 4°C. Following sonication, insoluble cell 
fraction was separated from soluble fraction by centrifugation at 14000rpm for 15 minutes. The 
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soluble fraction was removed and stored at -20°C. The insoluble fraction was resuspended in 1ml 
lysis buffer by sonication as vortexing posed insufficient. 
Table 2.3: Function of all components of chosen cell lysis buffer 
Reagent Function 
TritonX Non-ionic detergent improves solubility of GST fusion proteins 
and prevents aggregation of lysed cells. 
NaCl Provides an osmotic shock to cells 
Tris Interacts with lipopolysaccharides in the outer membrane of the 
cell and thereby increases permeability. 
EDTA Inhibits divalent cation-dependant proteases 
 
Protein expression was not detectable in either the soluble or insoluble fraction of the cell and 
therefore several lysozymes were introduced to the lysis buffer in a final concentration of 
0.1mg/ml. The insoluble fraction was incubated for 3 hours at room temperature on a rocker in 
the buffer containing lysozymes. Subsequently samples were centrifuged at 14000rpm for 15 
minutes and the supernatant was removed and stored at -20°C. The pellet was further 
resuspended as previously described to determine whether any expressed proteins remained in 
the insoluble fraction. 
2.3.6.2 Polyacrylamide gel electrophoresis SDS 
A 3% stacking and a 12.5% separation SDS-PAGE gel was used to separate proteins in a bio-rad 
system. Electrophoresis was run at 15mA/gel for 80 minutes in a Tris-glycine SDS running 
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buffer (25 mM Tris, 192 mM Glycine, 0.1% (w/v) SDS (pH 8.3)). The SDS-PAGE gel was then 
either stained in Coomassie Brilliant Blue stain (40% (v/v) methanol, 10% (v/v) acetic acid and 
0.025% (w/v) Coomassie Brilliant Blue (R250) overnight, to identify all proteins expressed in 
the cell, or transferred to a Western blot to identify the GST tag with the appended N-protein. 
Coomassie stain was removed using a coomassie destain solution (50% (v/v) methanol and 10% 
(v/v) acetic acid) and preserved in cellophane sheeting after treatment with gel drying solution 
(50% (v/v) methanol, 10% acetic acid and 10% (v/v) glycerol). 
2.3.6.3 Western transfer 
For Western blots, the proteins, separated by SDS-PAGE, were transferred to a nitrocellulose or 
PVDF membrane, where neither membrane had any noticeable preferential properties. Prior to 
transfer, the nitrocellulose membrane was equilibrated in 20% (v/v) methanol and the PVDF in 
100% (v/v) methanol. Proteins were transferred in transfer buffer (27mM tris(hydroxymethyl)-
amino-methane, 191mM glycine and 20% (v/v) methanol) in a submersion system at 100V for 
90 minutes, after which, the membrane was blocked with a 5% (w/v) milk and 0.05% (v/v) 
Tween- 20 in PBS solution for 30 minutes on a rocker. The membrane was then incubated at 4°C 
overnight on a roller in 3% (w/v) milk and 0.05% (v/v) tween 20 in PBS solution with the 
primary antibody, rabbitαGST, in a dilution of 1:5000. The membrane was then washed in a 
wash solution (0.05% (v/v) tween 20 in PBS) for 1 hour. The secondary antibody, HRP-
conjugated Goatαrabbit, was added in a dilution of 1:5000 in fresh solution previously described 
and incubated at room temperature for 1 hour on a roller, following which the membrane was 
washed in wash solution with subsequent addition of the peroxidase substrate. The presence of 
the GST-fusion protein was determined by colorimetric analysis.  
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2.4. RESULTS AND DISCUSSION 
E. coli is genetically easy to manipulate and inexpensive to culture, thus making it the preferred 
host for the expression of heterologous proteins. One of the disadvantages in using E.coli., 
however, is that it is incapable of undergoing any post-translational modifications, such as 
glycosylation, which is imperative for the production of active, folded proteins (Singh and Panda 
2005; Rinas, Hoffmann et al. 2007)  
2.4.1 PCR 
The HCoV-NL63 M, ORF3, E, ORF3ΔN and MΔN genes were amplified from cDNA generated 
by reverse transcription of the viral RNA. Primers used in amplification were designed to append 
the Sgf1 and Pme1 restriction enzyme cut sites to the amplicon. The Sgf1 cut site is located 
upstream of the start codon within the protein coding region. This will allow for the expression 
of untagged proteins as well as the N-terminal tagged region. The Pme1 cut site contains stop 
codon for the coding region of the protein and will add a Valine residue to the carboxyl terminus. 
As a result of these two enzymes cut sites, the reading frame and orientation of the insert is 
maintained. The gene sizes, as determined by the accession numbers from NCBI, were as 
follows:  M: 700bp; 0RF3: 678bp; E: 240bp; ORF3ΔN: 340bp and MΔN: 390bp. Following 
PCR, the products were run on a 1% (w/v) agarose gel and viewed under UV light (Figures 2.1 
to 2.5). The M, ORF3, E, ORF3ΔN and MΔN genes were identified as the correct size and gel 
excised for purification with a PCR gel Clean-Up kit (Promega). The viral genes were 
subsequently ligated into a pGEM® vector and used to transform JM109 strain competent E. 
coli.  
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Figure 2.1: PCR amplification of HCoV-NL63 M viral gene using primers described 
in table 2.1. Lane M: 100BP marker; Lane 1-6: HCoV-NL63 M-gene (±700bp); Lane 7: 
Blank; Lane 8: Negative control using all primers described in table 2.1. 
 
 
 
 
Figure 2.2: PCR amplification of HCoV-NL63 MΔN viral gene using primers 
described in table 2.1. Lane M: 100BP marker; Lane 1&2: HCoV-NL63 MΔN (±390bp); 
Lane 3-6: Blank. 
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Figure 2.3: PCR amplification of HCoV-NL63 ORF3 viral gene using primers 
described in table 2.1. Lane M: 100BP marker; Lane 1-4: HCoV-NL63 ORF3 (±678bp). 
 
 
 
Figure 2.4: PCR amplification of HCoV-NL63 E viral gene using primers described in 
table 2.1. Lane M: 100BP marker; Lane 1-: Negative control using all primers described in 
table 2.1. Lane 2-4: HCoV-NL63 E (±240bp). 
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2.4.2. Colony PCR of JM109 Competent E. coli 
Confirmation of the amplified genes of interest, based purely on the size observed following 
agarose gel electrophoresis, is not completely accurate. For this reason, amplicons were purified 
and subsequently ligated into the pGEM® T-easy vector for sequencing. This would also allow 
for identification of any base pair mutations. Recombinant pGEM® T-easy vectors were then 
transformed into JM109 competent E. coli. Following overnight incubation, colony forming units 
(CFUs) were selected and screened for insert using colony PCR (Figures 2.6 to 2.10). CFUs 
confirmed to contain the correct insert size were cultured overnight. From these, plasmids were 
extracted and confirmed by sequencing; all reported sequences were confirmed by determining 
the sequence for both strands. Forward and reverse sequences were aligned using the multiple 
sequence alignment tool ClustalX (Version 2.0.12) and viewed in GeneDoc (Version 2.7.000) 
(Appendix I). 
 
 
 
Figure 2.5: PCR amplification of HCoV-NL63 ORF3ΔN viral gene using primers 
described in table 2.1. Lane M: 100BP marker; Lane 1-: Blank; Lane 2: Negative control 
using primers described in table 2.1; Lane 3: HCoV-NL63 ORF3ΔN. 
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Figure 2.6: Detection of ORF3ΔN viral gene in JM109 competent E. coli transformed 
with pGEM® vector previously ligated with viral genes. Genes were detected using PCR 
with primers described in Table 2.1. Lane M: 100BP marker; Lane 1-7: Amplification of 
the ORF3ΔN gene (±360bp). All positive amplifications indicate successful ligation into the 
pGEM vector with subsequent transformation of JM109 competent E. coli with the ligation 
product 
 
 
 
Figure 2.7: Detection of ORF3 viral gene in JM109 competent E. coli transformed with 
pGEM® vector previously ligated with viral genes. Genes were detected using PCR with 
primers described in Table 2.1. Lane M: 100BP marker; Lane 1-: Blank; Lane 2-4&6-8: 
Amplification of ORF3 gene (±678bp); Lane 5: Negative control using the primers 
described in Table 2.1. All positive amplifications indicate successful ligation into the 
pGEM vector with subsequent transformation of JM109 competent E. coli with the ligation 
product 
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Figure 2.8: Detection of M viral gene in JM109 competent E. coli transformed with 
pGEM® vector previously ligated with viral genes. Genes were detected using PCR with 
primers described in Table 2.1. Lane M: 100BP marker; Lane 1-3: Amplification of M 
gene (±700bp). Lane 2-4: Unsuccessful amplification of the N1 gene; Lanes 5-7: 
Amplification of the M gene. All positive amplifications indicate successful ligation into 
the pGEM vector with subsequent transformation of JM109 competent E. coli with the 
ligation product 
 
 
 
Figure 2.9: Detection of MΔN viral gene in JM109 competent E. coli transformed with 
pGEM® vector previously ligated with viral genes. Genes were detected using PCR with 
primers described in Table 2.1. Lane M: 100BP marker; Lane 1-5:  Amplification of MΔN 
gene (±390bp). All positive amplifications indicate successful ligation into the pGEM vector 
with subsequent transformation of JM109 competent E. coli with the ligation product 
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2.4.3. SgfI and PmeI Restriction 
Sequenced-confirmed viral gene inserts were excised from recombinant pGEM constructs and 
subsequently cloned into compatible restriction enzyme sites (SgfI and PmeI) of the pFlexi™ 
vector. First, to confirm the release of the insert from the recombinant pGEM constructs, digests 
were viewed on a 1% (w/v) agarose gel under UV light (Figure 2.11 to 2.13) and viral genes 
were identified by their sizes. Bands were then excised from the gel, purified and ligated into the 
Flexi™ protein expression vector, which was then transformed into KRX competent cells. 
Restriction enzyme digests of the recombinant pFLEXI-N constructs from a previous study (refer 
to Section 2.3.1) were also done at this stage to confirm presence of the inserts (Figure 2.14). 
 
 
 
 
Figure 2.10: Detection of Eviral gene in JM109 competent E. coli transformed with 
pGEM® vector previously ligated with viral genes. Genes were detected using PCR with 
primers described in Table 2.1. Lane M: 100BP marker; Lane 1&2: Amplification of E gene 
(±; Lanes 3: Blank; Lane 4: Negative control using all primers described in table 2.1. All 
positive amplifications indicate successful ligation into the pGEM vector with subsequent 
transformation of JM109 competent E. coli with the ligation product 
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Figure 2.11: Restriction of the pGEM® vector, with SgfI and PmeI, isolated from JM109 
competent E. coli to remove ORF3ΔN and MΔN viral genes. Lane M: 100BP marker; Lane 
1: HCoV-NL63 ORF3ΔN (±360bp); Lane 2&3: HCoV-NL63 MΔN (±360bp); Lane 4: 
Negative control. All viral genes have an appended 5’ SgfI and a 3’ PmeI restriction site to 
allow for digestion with respective enzymes and subsequent ligation into the Flexi™ vector. 
 
 
 
Figure 2.12: Restriction of the pGEM® vector, with SgfI and PmeI, isolated from JM109 
competent E. coli to remove E viral genes. Lane M: 100BP marker; Lane 1-3: HCoV-NL63 
E. These viral genes have an appended 5’ SgfI and a 3’ PmeI restriction site to allow for 
digestion with respective enzymes subsequent ligation into the Flexi™ vector. 
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Figure 2.13: Restriction of the pGEM® vector, with SgfI and PmeI, isolated from JM109 
competent E. coli to remove M and ORF3 viral genes. Lane M: 100BP marker; Lane 1-3: 
cut pFLEXI vector (~4.2kbp); Lane 4: Negative control; Lane 5 HCoV-NL63 ORF3 
(±678bp); Lane 6: HCoV-NL63 M (±700bp); All viral genes have an appended 5’ SgfI and a 
3’ PmeI restriction site to allow for digestion with respective enzymes and subsequent ligation 
into the Flexi™ vector. 
 
 
 
Figure 2.14: Restriction enzyme digest of recombinant N vector constructs: Lane M: 
100BP marker. Lane 1: SARS N-gene (±1200BP); Lane 2: NL63 full length N-gene 
(±1100BP) (N1); Lane 3: 5’ half of the NL63 N-gene (±550BP) coding for the N-terminal 
fragment of the N-protein (N2); Lane 4: 3’ half of the NL63 N-gene (±550BP) coding for the 
C-terminal fragment of the N-protein (N3)  
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2.4.4. Colony PCR of KRX Competent E. coli 
To confirm ligation of the various inserts into the Flexi™ vectors, CFUs were inoculated into a 
culture and corresponding PCR reaction and viral genes were amplified as previously described. 
Results were again used to select successfully transformed colonies (Figure 2.15 to 2.19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15: Colony PCR of KRX competent E. coli previously transformed with Flexi™ 
vector ligated with ORF3ΔN-genes. Colony PCR was performed with primers described in 
Table 2.1 and used as confirmation of successful transformation and ligation Lane M: 
100BP marker; Lane 1-7: amplification of the ORF3ΔN-gene (±360bp). All successful 
amplifications of viral genes represent colonies, picked from agar plates, which were 
successfully transformed with the respective Flexi™-viral gene construct. 
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Figure 2.17: Colony PCR of KRX competent E. coli previously transformed with Flexi™ 
vector ligated with M-genes. Colony PCR was performed with primers described in Table 
2.1 and used as confirmation of successful transformation and ligation Lane M: 100BP 
marker; Lane 1&3-7: Amplification of the M- gene(±700bp); Lane 2&8: Blank. All successful 
amplifications of viral genes represent colonies, picked from agar plates, which were 
successfully transformed with the respective Flexi™-viral gene construct. 
 
 
 
Figure 2.16: Colony PCR of KRX competent E. coli previously transformed with Flexi™ 
vector ligated with E-genes. Colony PCR was performed with primers described in Table 
2.1 and used as confirmation of successful transformation and ligation Lane M: 100BP 
marker; Lane 1-7: amplification of the E-gene (±240bp). All successful amplifications of viral 
genes represent colonies, picked from agar plates, which were successfully transformed with 
the respective Flexi™-viral gene construct. 
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Figure 2.18: Colony PCR of KRX competent E. coli previously transformed with Flexi™ 
vector ligated with MΔN-genes. Colony PCR was performed with primers described in 
Table 2.1 and used as confirmation of successful transformation and ligation Lane M: 
100BP marker; Lane 1, 2&8: Amplification of the MΔN- gene (±390bp); Lane 3-7: 
Unsuccesful amplification of MΔN- gene; Lane 9: Negative control. All successful 
amplifications of viral genes represent colonies, picked from agar plates, which were 
successfully transformed with the respective Flexi™-viral gene construct 
 
 
 
Figure 2.19: Colony PCR of KRX competent E. coli previously transformed with Flexi™ 
vector ligated with ORF3-genes. Colony PCR was performed with primers described in 
Table 2.1 and used as confirmation of successful transformation and ligation Lane M: 
100BP marker; Lane 1-6: Amplification of the ORF3-gene (±678bp); Lane 7: Negative 
control; Lane 8-11: Amplification of the ORF3-gene. All successful amplifications of viral 
genes represent colonies, picked from agar plates, which were successfully transformed with 
the respective Flexi™-viral gene construct. 
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In addition to restriction endonuclease digests (see 2.4.3), a colony PCR was also initially done 
to confirm insert size. Figure 2.20 A and B indicates the successful transformation of 
nucleocapsid genes onto KRX cells From these figures it is clear that the nucleocapsid constructs 
were successfully cloned and transformed into KRX competent cells. 
 
 
 
 
 
 
 
 
 
 
 
2.4.5 Bacterial Expression of Recombinant Viral Proteins 
The Flexi™ vector system contains a chromosomal copy of the T7 RNA polymerase gene that 
has a rhamnose promoter to control recombinant protein expression. Although the T7 
polymerase system like this facilitates higher level of expression, they are prone to leaky 
expression. The presence of an unstable promoter sequence in an expression vector has been 
 
 
Figure 2.20 Colony PCR confirming the presence of construct that have been transformed 
into KRX cells (A) Lane M: 100BP marker; Lane 1: Blank; Lane 2: Negative control using all 
primers described in table 1 and 2; Lanes 3-9: Amplification of SARS N. (B) Lane M: 100BP 
marker; Lane 1-3: Amplification of N1 gene. Lane 4: Unsuccessful amplification of the N1 
gene; Lanes 5-8: Amplification of the N2 gene; Lanes 9-12: Amplification of the N3 gene; 
Lanes 13-16. 
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previously seen to result in low levels of toxic protein expression in both the initial and lag 
phases, as was observed in our study. (Weickert, Doherty et al. 1996; Giacalone, Gentile et al. 
2006). 
In this study, the expression protocol used included sub-culturing of starter cultures into an 
expression culture at a dilution of 1:100. Cultures were then grown to an OD600 of 0.3-0.4 (Table 
2.4), at which point expression was induced by the addition of 1mM IPTG and 0.1% rhamnose. 
Cells were harvested 5 hours post-induction and lysed using protocols as previously described. 
Table 2.4: OD600 (mg/ml) of cultures after time specified 
 Starter Culture 5 hours post-induction 
Uninduced 0.63 0.73 
E 0.57 0.40 
M 0.62 0.44 
ORF3 0.57 0.57 
ORF3ΔN 0.58 0.63 
ORF3ΔN 0.62 0.57 
 
As shown in Table 2.4, the expression of the viral-GST fusion proteins decreased the OD600 
readings in comparison to the un-induced control. This suggests possible toxicity of the proteins 
to the bacterial cell, which would explain the difficulty in modifying protocols for successful 
expression of the viral proteins (the Western blots for the modified expression protocols can be 
found in Appendix II). In a biological system like E. coli, protein expression will occur at a 
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subcellular location during a defined period of time and quantity (Peti and Page 2007). This 
expression of a foreign protein occurs at a significantly higher level than normal, and as a result 
of this over-expression creates a metabolic burden on the host cell (Bianchi and Baneyx 1999). 
This often results in a low cell density, as seen in our OD readings obtained pre- and post-
rhamnose induction. In addition, the presence of background expression at a high level could 
indicate a further reduction in bacterial growth, delaying the onset of a bacterial equilibrium 
phase (Glick 1995; Georgiou and Valax 1996). Induction usually occurs at the final bacterial 
growth phase, when all the glucose in the media is metabolised and the cells now begin to use 
the L-Rhamnose that allows expression to occur. 
M and E glycoproteins failed to express. Since both are membrane-bound proteins, the former 
could be due to the interaction with cellular membranes. A previous study by Lia et al has also 
shown that the E protein is able to slow E. coli growth by increasing membrane permeability and 
subsequently leading to cell lysis. (Liao, Lescar et al. 2004). Also, other membrane proteins 
simply fail to express in E. coli and, if they do express, they do so via the formation of an 
insoluble product called an inclusion body (Shimamoto, Kasciukovich et al. 1998; Singh and 
Panda 2005). An inclusion body is a dense aggregate that is formed between an expression 
fusion protein and RNA, decreasing the yield of purified protein (de Groot, Espargaro et al. 
2008; Alibolandi and Mirzahoseini 2011; Garcia-Fruitos, Vazquez et al. 2012). As a result, the 
need to solubilise these proteins becomes a crucial step in obtaining a high concentration of the 
protein of interest. There are various solubilising techniques available; however the efficacy of 
each method is dependent on the protein being expressed. 
In an attempt to express the previously cloned SARS-N, HCoV-NL63 N1, N2 and N3 proteins, 
we found that there was a need to solubilise said proteins in order to obtain a workable 
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concentration for further studies. To do this, the insoluble fraction was treated with lysozymes as 
this technique does not have an impact on the expressed proteins obtained.  Lysozymes digest the 
peptidoglycan layer of the bacterial cell wall, and are a relatively inexpensive means to solubilise 
insoluble proteins. Figure 2.21 shows the expression results obtained after the treatment of the 
cell pellet with lysozymes in the same buffer used for lysis. Expression of the proteins of interest 
indicates that heterologously expressed viral-fusion proteins interact with bacterial cellular 
membranes. In this study a variety of growth factors were investigated to provide a greater yield 
of non-degraded soluble proteins. These included lower growth temperature between 20°C and 
30°C, inducing for a shorter period and increasing aeration, all of which proved unsuccessfully in 
detecting the E, M, ORF3 proteins in the soluble or insoluble fractions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.21: Digestion of cellular membranes using lysozymes to release membrane-bound, 
insoluble proteins. (A) Western blots representing proteins which remained in the insoluble 
fraction following digestion with lysozymes. (B) Proteins made soluble following digestion 
with lysozymes.(A) Lane M: Prestained molecular weight protein marker; Lane 1: Uninduced 
control; Lane 2: GST-SARS N; Lane 3: GST-N1; Lane 4: GST-N2; Lane 5: GST-N3. Lane order 
is again maintained for B. 
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In a further attempt to maximise expression of the E, M and ORF 3 fusion proteins the KRX 
strain proved to be the most suitable E.coli strain as it is deficient of any cytoplasmic protease 
genes, causing lower protein degradation. However, the rhamnose-inducible system is not a 
widely used system when compared to the common IPTG-inducible system that boasts extensive 
troubleshooting techniques. Therefore the E, M and N proteins were also cloned in a pGEX -4T-
2 system to determine if the proteins are indeed toxic (Appendix III; Cloning was done as part of 
this Chapter, but expression of these proteins will form part of another study). Even so, the 
Flexi™ vector still proved to be a suitable system for the cloning and expression of the HCoV-
NL63 N and SARS-CoV N proteins. 
Table 2.5:-Expression of the HCoV-NL63 structural proteins 
Construct Structural 
Protein 
Expression in this study Source of the construct 
E-pFLEXI  E-GST - This study 
M-pFLEXI M-GST NR This study 
ORF3-pFLEXI ORF3-GST - This study 
MΔN-pFLEXI MΔN-GST - This study 
ORF3ΔN-pFLEXI ORF3ΔN-GST - This study 
SARS-N-pFLEXI SARS-N-GST + Berry et al, 2012 
N1-pFLEXI N1-GST + Berry et al 2012 
N2-pFLEXI N2-GST + Berry et al 2012 
N3-pFLEXI N3-GST + Berry et al 2012 
-: No expression; NR: Not repeatable; +: Expression 
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Our study concluded that the E, M and ORF3 proteins are toxic to the KRX E. coli strain, but 
further improvements could still be investigated before completely discounting this system for 
use in the expression of these proteins (Table 2.5). One such improvement could be the inclusion 
of a Kozak sequence located upstream on the mRNA. This consensus sequence has been shown 
to play a major role in the initiation of translation, as well as increasing protein expression 
without altering the nucleotide sequence of the amplified gene (Kozak 1984; Kozak 1986; 
Seeber 1997). A bacterial system is easy to use and high expression levels are often attained, but 
one major drawback is the frequent inability to synthesise native eukaryotic proteins. For this 
reason an expression system like the vaccinia virus vector system is useful. The vaccinia vector 
uses components from the bacteria in a eukaryotic model, to offer a highly efficient and specific 
solution for eukaryotic protein synthesis (Moss and Earl 2002). This expression system 
synthesises the bacterial T7 RNA polymerase in the cytoplasm as opposed to the nucleus of 
infected cells. As a vector, vaccinia virus has a number of useful characteristics, including a 
capacity to clone large fragments of foreign DNA (20+ kbp) with retention of infectivity, a wide 
host range, a relatively high level of protein synthesis (Moss and Earl 2001) 
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HCoV-NL63 nucleocapsid stimulates an immune 
response in whole blood cultures: A pilot study 
 
 
 
 
 
 
 
 
 
 
3.1 ABSTRACT  
This chapter is prepared for submission as a Short Communication to Archives of 
Medical Sciences. For this reason, the format of this Chapter is different to that of 
Chapter II.  
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The Human coronavirus-HCOV-NL63 (HCoV-NL63) was first isolated in 2003 from the 
nasal aspirate of an infant. This virus is closely related to the severe acute respiratory 
coronavirus (SARS-CoV), but unlike SARS-CoV, HCoV-NL63 circulates continuously in 
the human population. Recent studies have focused on the effect of coronavirus infections on 
the host immune response, in particular on the cytokines that are produced as a response to 
these virus infections. The coronavirus nucleocapsid (N) protein is a multifunction protein 
and plays an important role in viral assembly and pathogenesis. In this study, the effects of 
the HCoV-NL63 N protein on the cytokines that regulate immune responses in lymphocytes 
were determined. Full-length as well as deletion-mutants of HCoV-NL63 N protein were 
expressed in Escherichia coli KRK cells and column-purified. Cellular responses induced by 
these recombinant N proteins were evaluated in whole blood culture. A double antibody 
sandwich ELISA assay was used to measure the immune responses; interferon-gamma (IFN-
γ), interleukin-10 (IL-10) and interleukin-6 (IL-6) responses against the N proteins were 
observed. While lymphocyte activation resulted in high expression levels of IL-6, IFN-γ and 
IL-10, cytokines were secreted at much lower levels. This study showed that the HCoV-
NL63 N protein elicits a broad-based cellular immune response. 
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3.2. INTRODUCTION 
Coronaviruses are among the most common causes of respiratory infections, accounting for 
10-30% of respiratory infections (Bastien, Robinson et al. 2005). Coronaviruses are a family 
of 27-32kb sized RNA viruses that have a positive sense single-stranded genome with helical 
genetic symmetry that infect mammalian and avian hosts (van der Hoek, Sure et al. 2005).  
It was initially believed that there were only two human coronaviruses (HCoV) in circulation: 
HCoV-OC43 and HCoV-229E (van der Hoek, Pyrc et al. 2006) With the exception of SARS-
CoV, it was commonly believed that human coronaviruses caused only mild respiratory tract 
infections (Monto and Lim 1974) As a result, the presence of HCoV within the population 
was not monitored. In the 1960s (McIntosh 2005), six samples with essentially different 
viruses causing URTs were isolated from patients, four of which shown to be serologically 
distinct (Tyrrell and Bynoe 1965; Hamre and Procknow 1966; Almeida and Tyrrell 1967). 
These four clinical samples were unfortunately lost prior to characterisation and consequently 
focus was directed at the two remaining samples. This resulted in HCoV-229E and HCoV-
OC43 being well characterised. Additionally, the detection of HCoV-NL63 in samples 
collected in 1981 (Talbot, Shepherd et al. 2009) and 1988 (Fouchier, Hartwig et al. 2004) 
indicates that the virus has been circulating in the human population for a considerable 
amount of time, and it is unknown whether these represent the same strain as the previously 
lost HCoV’s. (Pyrc, Dijkman et al. 2006). The detection of SARS-CoV, however, showed 
that coronaviruses are able to undergo considerable recombination that can result in a more 
lethal form of the virus. SARS-CoV is characterised by symptoms such as fever, myalgia, a 
non-productive cough and dyspnea, and has lead to more than 8000 infections in children and 
800 deaths in 26 countries (Cheng, Lau et al. 2007). 
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This increased interest and research into CoVs has led to the discovery of two new human 
coronaviruses, HKU1 (Woo, Lau et al. 2005) and HCoV-NL63 (Pyrc, Berkhout et al. 2007). 
Infection with HCoV-NL63 presents with common cold-like symptoms such as fever, sore 
throat, and rhinitis (Pyrc, Jebbink et al. 2004; Vabret, Mourez et al. 2005; Han, Chung et al. 
2007; Kuypers, Martin et al. 2007; Wu, Chang et al. 2008; Fielding 2011). HCoV-NL63 is 
also associated with acute respiratory illness and croup in young children, the elderly and 
immune-compromised patients. (Pyrc, Jebbink et al. 2004). Studies have found that between 
1.0 and 9.3% of respiratory tract infections in children have been positive for HCoV-HCOV-
NL63 (Fielding 2011) with 75% of children aged 2.5-3.5 years being sero-positive for 
HCoV-NL63 (Dijkman, Jebbink et al. 2008). 
To date, research groups in Canada, Brazil and Denmark have all reported fatalities following 
infections by HCoV-NL63 (Bastien, Anderson et al. 2005; Oosterhof, Christensen et al. 2010; 
Cabeca and Bellei 2012). This indicates that HCoV-NL63 could play a crucial role in more 
severe respiratory diseases. In the Denmark report, a patient that underwent an allo-
haematopoietic cell transplant presented with influenza-like symptoms five months after 
surgery. Clinical samples of the tracheal and nasopharyngeal fluid tested negative for various 
respiratory viruses such as the RSV, influenza A and B, para-influenza virus, meta-
pneumovirus, adenovirus and rhinovirus. PCR of the bronchlear lavage fluid tested positive 
for HCoV-NL63. The patient’s condition continued to deteriorate and, five weeks after 
admission into hospital, the patient died as a result of progressive respiratory failure. This 
isolated case, along with the previously mentioned reports in Canada and Brazil, all presented 
with a suppressed or compromised immune systems, indicating that routine screenings for 
coronaviruses in particular HCoV-NL63 should be conducted. (Oosterhof, Christensen et al. 
2010). 
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Phylogenetic analysis using complete genomes have divided coronaviruses into three distinct 
groups (Liu and Sun 2008). However, the International Committee for Taxonomy of Viruses 
(ICTV) recently proposed that these three groups be replaced by three new genera, namely 
Alpha-, Beta-, Gamma-and Delta-coronavirus(Woo, Huang et al. 2010).HCoV-NL63 belongs 
to the group I coronaviruses, according to phylogenetic analyses. The highest similarity is 
observed with HCoV-229E and porcine epidemic diarrhoea virus (PEDV), 65% and 61%, 
respectively (van der Hoek, Pyrc et al. 2004) HCoV-NL63 also presents with symptoms 
similar to those caused by other coronaviruses. This makes the identification of the causative 
coronavirus based solely on the observation of symptoms in patients difficult. (Koetz, Nilsson 
et al. 2006).  
Coronaviruses have a positive sense single-stranded RNA genome, approximately 25-30kbs 
in size. There are four major structural proteins that are encoded by the genome; these are the 
spike (S), membrane (M), envelope (E), and the nucleocapsid (N) proteins. Of these 
structural proteins, the coronavirus nucleocapsid protein is the most abundantly expressed 
protein with an infected cell (Surjit, Liu et al. 2004; Hsieh, Chang et al. 2005; Zuniga, Sola et 
al. 2007) The N protein is responsible for several functions, one of the most vital being the 
binding to viral RNA to allow for the formation of the ribonuclocapsid core(Hsieh, Chang et 
al. 2005). The N protein is also believed to play a role in the replication, transcription and 
translation of the virus (Sawicki, Sawicki et al. 2007). 
Currently, the N proteins plays a role in several functions, including the inhibition of 
interferon production (Kopecky-Bromberg, Martinez-Sobrido et al. 2007), the up-regulation 
of the AP1 signal transduction pathway (He, Leeson et al. 2003), interaction with various 
cellular proteins including cyclophilin A (Luo, Chen et al. 2005) as well as the deregulation 
in the host cell cycle (Surjit and Lal 2008). 
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Several studies have shown that the N protein of the order Nidovirales localises to the 
nucleus or the nucleolus (Hiscox, Wurm et al. 2001; Timani, Liao et al. 2005). On the other 
hand, some studies have also shown that the N protein may in fact localise to the cytoplasm 
(Rowland, Chauhan et al. 2005; You, Dove et al. 2005) . These two opposing findings 
indicate that the localisation of the N protein is not a conserved process in all the nidoviruses. 
The N protein is proposed to be an important target protein in the development of effective 
coronavirus diagnostic tools. This is due to that fact that the N protein has been shown to be 
highly antigenic and is thus able to induce an effective antibody response in the host cell 
(Leung, Tam et al. 2004). 
In addition, several reports have shown that the SARS-CoV N protein, as is with other 
coronaviruses, induces a specific T cell response and also interferes with various cellular 
pathways, indicating that the N protein can play a crucial regulatory role (Hogue 1995; 
Narayanan, Maeda et al. 2000; Narayanan, Chen et al. 2003). The importance of this in 
relation to host immune response is unknown and warrants further investigation. 
The host immune response to HCoV-NL63 N is still not well understood. Therefore, this 
chapter focuses on characterization of the host immune response to HCoV-NL63 N in human 
whole blood culture. Recombinant HCoV-NL63 full-length N, as well as two deletion 
mutants, expressed in a bacterial cell system, were used to treat whole blood cultures. An 
ELISA was used to measure pro- and anti-inflammatory activity after 18 hours. A statistically 
significant IL-6 response was detected, indicating that all HCoV-NL63 recombinant N 
proteins stimulated an inflammatory response. 
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3.3. MATERIALS AND METHODS 
3.3.1 Protein expression and preparation of cell lysate  
Selected plasmids from the glycerol stocks mentioned in 3.1 were spread-plated and grown 
overnight at 37°C. Thereafter a single colony was selected from the plates and grown for 14 
hours at 37°C in 10 ml LB (10 g pancreatic digest of casein, 5 g yeast extract powder, and 5 g 
NaCl, per 1L water) broth containing ampicillin (1.0 mmol/L) as an antibiotic. These were 
diluted 1:100 with LB containing ampicillin, and thereafter they were grown at 37
o
C with 
shaking. Protein expression was induced with 0.05% (w/v) glucose and 0.1% (w/v) 
Rhamnose. At 8 hours, post-induction cells were harvested by centrifugation at 6000rpm for 
15 minutes at 4°C to prevent protein degradation. Dry cell pellet was frozen at -80°C until 
further use. Every 2 grams of cells were resuspended in 2ml of lysis buffer (1% (v/v) 
TritonX, 150mM NaCl, 10mM Tris (hydroxymethyl)-amino-methane (Tris), 5mM EDTA 
and a protease inhibitor. Cells were lysed by sonication for 3 minutes at 30-second intervals 
in an ice bath to prevent protein degradation. Following sonication, insoluble cell fractions 
were separated from soluble fractions by centrifugation at 14000rpm for 15 minutes at 4°C. 
The insoluble fraction was discarded and the soluble supernatant was stored at -20°C until 
further use. 
 
3.3.2 Protein analysis  
3.3.2.1 SDS Page 
For SDS-PAGE analysis, sterile gel plates were assembled and verified for any leakages. 
15% of SDS gel was prepared using these plates according to the Fluka specifications. For 
quality purpose, APS (10%w/v) was prepared every week. Prior to sample loading into gel 
wells, a 1.5:1 mix ratio of protein sample with loading dye was performed. Approximately 25 
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μl and 10 μl of total protein and protein marker, respectively, were loaded into protein wells. 
These were separated according to their electrophoretic ability, applying constant current at 
20 amperes per gel. Following this reaction the gel was either submerged in Commassie stain 
(45 % methanol, 10 % glacial acetic acid, 45 % water, and 3 g/L Coomasie brilliant blue 
R250) overnight or subjected to Western blotting for further experiments. 
 
3.3.2.2 Western blot 
The separated proteins were transferred to a nitrocelullose membrane for Western blot 
studies. The SDS gel was transferred to a Western blot transfer system covered with 
nitrocelullose membrane that has been sandwiched with Whatmann paper and sponges 
immersed in pre-cooled transfer buffer. The experiment was carried out at 4°C with the 
transfer system running at 100 V and constant amperes for a period of 120 min.  
On completion of the transfer, the nitrocellulose membrane was immersed in Ponceau stain 
with shaking for 3 minutes and then blocked with 3% (w/v) milk for approximately 30 
minutes. The membrane was then incubated in 3% (w/v) milk and 0.05% (v/v) tween 20 PBS 
solution with a rabbit anti-GST, primary antibody in a ratio of 1:5000 overnight at 4
o
C. This 
was followed by a washing step with PBS containing 0.05% Tween-20 for 45 minutes, and 
then covered with a secondary antibody, peroxidase-labeled goat anti-rabbit for 60 minutes in 
a 1:2000 ratio. The membrane was again washed twice with PBS/0.05% Tween-20 at 30 
minute intervals, after which 1000 μl of 1 Component TMB membrane peroxidase substrate 
was added on the membrane to detect the presence of recombinant protein from the total 
bacterial proteins. The presence of the protein of interest was indicated by the appearance of a 
purple colour on the nitrocellulose membrane. 
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3.3.2.3 Quantification of protein concentrations 
For quantification of proteins, a Qubit-iTTM Assay was used. Also, 199 x n μl of Quant-
iTTM buffer (where n represents the number of standards plus number of samples) was 
mixed up with 1 x n μl of Quant-iTTM reagent to a make up a Quant-iTTM working solution. 
190 μl of the latter was then mixed with 10 μl of standards, whereas 180-199 μl of working 
solution was mixed with user samples to make up a final volume of 200 μl. Following 
equilibration of the QubitTM fluorometer with known standards, fluorometer readings were 
taken and the concentrations (mg/ml) were calculated using the formula C = QF x 200/10 
(where QF = Qubit fluorometer reading, C = concentration). 
 
3.3.2.4 Purification  
A MagneGST™ purification system was then utilised to bind GST fusion proteins. The 
MagneGST™ particles were equilibrated by washing 3 times in the MagneGST™ 
binding/wash buffer (4.2mM Na2HPO4, 2mM K2HPO4, 140mM NaCl, 10mM KCl). 
Particles were separated from the binding/wash buffer by placing tubes in the magnetic stand. 
Glutathione particles were then resuspended in 250μl binding/wash buffer and 25μl lysozyme 
treated pellet, and 25μl soluble fraction was added and incubated at room temperature on an 
orbital shaker for 30 minutes. Glutathione particles (now bound to GST fusion proteins) are 
isolated in the magnetic stand and washed 3 times in the binding/wash buffer. The particles 
were then resuspended in 100μl elution buffer (50mM Glutathione, 50mM Tris-HCl) and 
incubated at room temperature for 30 minutes on an orbital shaker. Particles are again 
separated in the magnetic stand and the supernatant (containing the purified GST fusion 
proteins) was removed and stored at -20°C.  
 
3.3.3 Whole blood cytokine assays  
 
 
 
 
Chapter III 
87 
 
 3.3.3.1. Blood sample collection 
 
Blood was obtained from healthy, male volunteers and stored at ambient room temperature. 
Consent was obtained from all participants. Blood samples were collected in 10 ml citrate-
containing vacuum tubes by veni-puncture and used within 8 hours of collection. All 
procedures were performed under sterile conditions. Whole blood was diluted 1:10 with 
Roswell Park Memorial Institute (RPMI)-1640 (Sigma-Aldrich, Germany) before being 
stimulated with the full-length SARS-COV and HCOV-NL63 N and Deletion Mutant 
proteins. 
3.3.3.2. ELISA test to measure cytokine production 
Cytokine production was measured in the supernatants, following incubation with the 
recombinant viral proteins for 18 hours. In this study, human blood was treated with the B-
cell mitogen, lipopolysaccharide (LPS) and the T cell mitogen, phytohemagglutinin, (PHA) 
which served as controls. Whole blood culture supernatants were screened for IL-6 as a 
biomarker of inflammation, IFN-γ as a biomarker of cell mediated immunity and IL-10 as a 
biomarker for humoral immunity. Cytokine production by whole blood cultures were 
measured using ELISA kits (eBioscience, USA). The kits contained all reagents required for 
the assay. Briefly, 96-well plates (Nunc-Immuno plate, Serving Life Science, Denmark) were 
coated with 100 μl pre-titrated purified capturing antibody per well diluted in coating buffer 
and incubated overnight at 37°C. After 5 washes with wash buffer (autoclaved phosphate 
buffered saline containing 0.05 % Tween-20), non-specific binding sites were blocked with 
assay diluent for 1 hour at room temperature. 50 μl supernatants were then added to their 
respective wells. Recombinant human cytokine standards were also included on each plate to 
generate standard curves and calibrate samples. The plate was sealed and incubated at room 
temperature for 2 hours. After 5 washes, 100 μl of detection antibody (Biotin-conjugated 
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anti-human cytokine) was added to each well. The plate was incubated for 1 hour at room 
temperature. The plate was washed again 5 times and the biotineylated sandwich was 
detected by adding 100 μl of the Avidin-horseradish peroxidase conjugate (HRP) to all wells. 
The plate was then incubated for 30 minutes at room temperature. After 7 washes the bound 
peroxidase was monitored by adding 100 μl of the substrate solution (Tetramethlybenzidine 
solution) to every well. The plate was incubated for approximately 15 minutes at room 
temperature after which the reaction was stopped by the addition of 50 μl stop solution to all 
wells. Absorbance was read at 450 nm on an ELISA plate reader. 
3.3.3.3 Statistical Analysis  
All data was statistically analysed via one-way ANOVA using SigmaStat software (Systat 
Software Inc., USA). All cytokine assays were conducted in triplicates and repeated 4 times 
to avoid statistical errors. Results were expressed in terms of the mean ± standard deviation 
or the mean ± standard error of the mean (SEM). 
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3.4 RESULTS 
3.4.1 Expression of the recombinant viral proteins 
Proteins were successfully expressed and analysed using SDS-PAGE, and Western blot. 
Figure 3.1 represents total proteins that were expressed in a bacterial system.  
 
 
 
 
 
 
 
 
 
 
 
 
3.4.2 Purification of the recombinant proteins by MagneGST™ 
The purification of recombinant protein was conducted using the MagneGST protein 
purification system. Following the optimisation of protein expression, the presence of the 
nucleocapsid proteins was confirmed by small-scale purification; this is clearly shown in 
Figure 3.2 below. 
 
 
 
 
Figure 3.1 Western blot analyses if recombinant proteins expressed in bacterial cell 
in the soluble fraction. On the figure, M represents the pre-stained protein marker. Lane 
1-4 represents detected proteins in the following order: SARS-CoV N, N1, N2, and N3. 
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3.4.3 Quantification of protein concentrations 
 
Table 3.1.represents the purified protein concentrations obtained using the Qubit-iTTM system. 
Construct  Concentration (mg/ml) 
SARS-COV-N 0.45 
N1 0.11 
N2 0.34 
N3 0.18 
 
 
 
 
 
Figure 3.2: Coomassie stain of GST fusion viral proteins, purified using the 
MagneGST™ purification system. “M” indicates the protein marker. Lane 1-4 represent 
purified proteins in the following order: SARS-CoV-N, N1, N2, and N3 
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3.4.4 The effect of Nucleocapsid viral proteins on unstimulated whole blood cultures 
IL-6 synthesis was used as a biomarker to detect an inflammatory response in LPS 
unstimulated whole blood cultures. Figure 4.5 illustrates a typical standard curve used to 
determine IL-6 secretion in WBCs incubated with various viral proteins. A polynomial 
relationship between OD and IL-6 synthesis (pg/ml), with a correlation coefficient of 0.997, 
was observed. Upon PHA stimulation of WBCs, the T cell derived cytokines IFN-γ and IL-10 
are produced. IFN-γ was used as a biomarker for cell mediated immunity and IL-10 as a 
biomarker to determine the humoral immune response. Figure 4.3 also illustrates the typical 
standard curves constructed to determine IFN-γ and IL-10 synthesis in WBCs exposed to 
viral proteins. A linear progression for both IL-10 and IFN-γ standard curves, with 
correlation coefficients of 0.985 and 0.998, respectively, were observed.  
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3.4.5 The inflammatory activity of the recombinant viral proteins 
 
Results show that all the recombinant viral proteins are significantly different from the 
positive control LPS. But HCoV-NL63 full length N protein (N1) and the truncated clones 
N2 and N3 released the higher levels of IL-6 when compared to SARS-CoV-N. 
Figure 3.3 Standard curves for IL-6, IFN-γ and IL-10 synthesis (pg/ml) versus 
OD (450 nm). A polynomial relationship for the IL-6 standard curve with a 
correlation coefficient of 0.993 was generated. Standard curves obtained for IL-10 
and IFN-γ showed a linear progression with correlation coefficients of 0.985 and 
0.998, respectively.  
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Figure 3.4 presents the average IL-6 concentrations obtained for all three donors on 
incubation with the various proteins.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.6 Effect of recombinant viral proteins on T-cell differentiation 
Figures 3.5 and 3.6 represents the average IL-10 and IFN-γ levels obtained for all donors 
treated with the viral proteins. Results for IL-10 show that all viral proteins reacted equally 
when compared to the positive control, PHA. These results reflect that the N proteins of both 
SARS-COV and HCOV-NL63 may not have an effect on the humoral immune response. 
IFN-γ has been shown to enhance the activation of macrophages as well as antibody 
dependent cellular cytoxicity. This form of immune response serves as a defence against 
intracellular pathogens ((Langezaal, Coecke et al. 2001) and the comparison of the various 
 
 
Figure 3.4 Induction of IL-6 (pg/ml) of whole blood cultures in the presence of 
10µg/ml of viral proteins various and distilled water (control). Each point 
represents the mean and standard deviation of three replicates. An asterisk (*) 
designates significant difference to the control (P<0.05). 
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viral proteins to the control, PHA, showed that none of the proteins had an effect on IFN-γ 
synthesis and, subsequently, cell-mediated immunity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Induction of IL-10 (pg/ml) of whole blood cultures, in the presence of 
10µg/ml of the recombinant viral proteins and distilled water (control). Each point 
represents the mean and standard deviation of three replicates (n=12). An asterisk (*) 
designates significant difference to the control (P>0.05). 
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4.5. DISCUSSION AND CONCLUSION 
Stimulation of the innate immune response is important for the control and elimination of 
invading pathogens. As a result, an interaction between a virus and innate immune mediators 
will allow for the limitation of viral spread within the host system during the early phases of 
disease (Katze, He et al. 2002). Studies have also shown that many viruses use a specific 
genes to encode products that are able to affect both the innate and acquired immune system 
responses (Symons, Alcami et al. 1995; Gale, Korth et al. 1997; Basler, Wang et al. 2000; 
Parisien, Lau et al. 2001; Park, Shaw et al. 2003; Andrejeva, Childs et al. 2004; Meylan, 
Curran et al. 2005; Ye, Hauns et al. 2007). It has been shown that the epithelial cells of the 
airways are a primary site for HCoV-NL63 infection, allowing for synthesis of many 
 
 
Figure 3.6 Induction of IFN-γ (pg/ml) of whole blood cultures, in the presence of 
10µg/ml of recombinant viral proteins and distilled water (control). Each point 
represents the mean and standard deviation (n=12). An asterisk (*) designates significant 
difference to the control (P<0.05). 
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cytokines. Therefore, an investigation into how these specific viruses and their viral proteins 
interact with the host innate immune system is essential to understand the way in which 
virulence and disease outcome is regulated. This present pilot study is the first to explore the 
cytokines that are produced when the HCoV-NL63 viral protein N interact with human whole 
blood cultures. 
In this study, human blood was treated with the B-cell mitogen - lipopolysaccharide 
(LPS) - and the T cell mitogen - phytohemagglutinin (PHA) -, which served as controls in our 
study. LPS stimulates an inflammatory response and initiates the release of IL-6 from 
monocytes and B-lymphocytes. On the other hand, PHA stimulates the cell mediated and 
humoral immune pathways, initiating the release of IFN-γ and IL-10 from T lymphocytes 
(Hussain, Kaleem et al. 2002).  
 
The isolation of peripheral blood mononuclear cells (PBMC) remains the most 
popular methods to measure ex vivo cytokine production as it is simple and less expensive. 
However PBMC cultures have been shown to have an inconsistent monocyte to lymphocyte 
ratio when compared to whole blood cultures (Popa, Barrera et al. 2009). Whole blood 
cultures on the other hand contain the efficient physiological proportions of blood bourn 
factors such as moncytes, lymphocytes and platelets that are able to maintain the cells their 
natural environment in vivo (Muller, Herner et al. 1998; Hussain, Kaleem et al. 2002) and as 
such can be used to accurately determine the immune response to various antigens and. Our 
study used whole blood cultures as we conclude that it is a well suited low cost method to 
measure monocytic cytokine production. Also, whole blood cultures can be carried out 
immediately after sampling and only requires the use of small volumes of blood to be 
obtained.  
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Our results showed that HCoV-NL63 N1, as well as N2 and N3, promoted the synthesis of 
the cytokine IL-6 (Figure 3.4). This is similar to the results of a previous study that showed 
that the SARS-CoV N protein activates IL-6 expression (Zhang, Wu et al. 2007). IL-6 is a 
pleiotrophic inflammatory cytokine that is produced by various cells including mononuclear 
phagocytes, fibroblasts and endothelial cells (Akira, Taga et al. 1993; Muller, Herner et al. 
1998; Papanicolaou, Wilder et al. 1998). It also plays a crucial role in cellular humoral 
responses, as well as in antibody production In addition, to identify the antigenic epitopes, 
Zhang and colleagues also used different regions corresponding to the N- and C-termini of 
the N protein in their study. They concluded that both the N- (86-96 amino acid regions) and 
the C-terminus (341-422 amino acid region) stimulate an increase in IL-6 activity. This 
agrees with our findings, as our study also showed that both N2 and N3 elicited similarly 
strong IL-6 responses; however, in our study this was donor dependent. The increased release 
of the IL-6 cytokine has also been reported for other coronaviruses, viz HCoV-OC43 and the 
Feline Infectious Peritonitis virus (Edwards, Denis et al. 2000; Foley, Rand et al. 2003). 
Various studies of SARS-CoV tissue pathology also show the presence of high levels of the 
IL-6 inflammatory cytokine (Zhang, Li et al. 2004; Huang, Su et al. 2005; Yu, Hu et al. 2005; 
Roberts, Deming et al. 2007). This up-regulation of IL-6 is probably due to a secondary 
response to the initial activation of the immune system (Thiel and Weber 2008). Taken 
together, our and previous IL-6 data, suggested that the recombinant HCoV-NL63 N proteins 
have the potential to induce an inflammatory action in a healthy immune system. 
 
The innate immune system response to SARS-CoV infection is related to the 
pathological changes that occur during disease progression (Huang, Su et al. 2005; Theron, 
Huang et al. 2005; Okabayashi, Kariwa et al. 2006). The synthesis of Type 1 interferon in 
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response to an intracellular pathogen, like a virus, is important for the effective functioning of 
the innate immune system during infection (Stark, Kerr et al. 1998; Takaoka and Yanai 
2006). In fact, SARS-CoV N suppresses IFN expression by targeting cellular recognition 
receptors on the host cells in the innate immune pathway (Frieman, Heise et al. 2008; Thiel 
and Weber 2008). The production of innate immune system cytokines during HCoV-NL63 
infection has not yet been studied in detail. Therefore, in this chapter, we looked at the 
response of two cytokines, namely IFN-γ and IL-10, to the treatment of whole blood with 
HCoV-NL63 N. Results for N1, N2 and N3 showed that HCoV-NL63 N did not stimulate 
IFN-γ secretion (Figure 3.6). This could indicate that the HCoV-NL63 N protein may have a 
low-level impact on cell mediated immunity, although there are no previous studies to 
support this. IL-10 is an anti-inflammatory cytokine produced by Th2 cells, which stimulates 
humoral immunity i.e. B cell activation and maturation resulting in antibody production 
(Storni, Kundig et al. 2005; Viveros-Paredes, Puebla-Perez et al. 2006). Results showed that 
none of the recombinant viral proteins had an impact on IL-10 synthesis. This could indicate 
that the HCoV-NL63 N1, N2 and N3 proteins do not have an immune-suppressive effect on 
humoral immune response system (Figure 3.5); however optimization and repetition of this 
experiment is required to substantiate this viewpoint. 
 
Although donors showed similar IL-6 responses, there were slight differences in the 
secretion levels of this cytokine (Figure 3.4.). This individual variability could be attributed 
to the fact that patient blood samples can rarely be standardised, as responses are dependent 
on the functionality of an individual’s existing immune system. Nonetheless, data obtained 
provided a vital understanding into the immune response elicited by the HCoV-NL63 N 
protein. Even though the results for this pilot study showed that HCoV-NL63 N stimulated a 
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pro-inflammatory response, further investigation to identify immuno-stimulatory epitopes for 
N is required. 
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The human coronavirus NL63 was discovered in 2004 and shown to be a clinically important 
virus. HCoV-NL63 affects mainly children, the immunocompromised and the elderly. 
Infection with HCoV-NL63 may result in upper respiratory infections and can also present 
with complications like asthma exacerbation, febrile seizures and high fever.  
The virus is assembled through the interaction of four main structural proteins, the 
spike (S), membrane (M), envelope (E) and the nucleocapsid (N). Of these structural 
proteins, the nucleocapsid protein is of vital importance in the formation of the 
ribonucleocapsid core via the interaction with viral RNA. Assembly occurs when the N 
protein undergoes N-N homotypic interactions and thereafter interacts with the viral RNA. 
The N protein has also been shown to interact with the M protein on the virus surface during 
the assembly process. In this study, molecular techniques were used to characterize the 
properties of the various HCoV-NL63 structural proteins.  
Using viral RNA as a template, RT-PCR was used to generate cDNA of the HCoV-
NL63 genome. The E, M, ORF3 as well as the hydrophilic regions of the ORF3 (ORF3ΔN) 
and M (MΔN) proteins were PCR amplified and ligated into the pGEM® T-easy vector for 
sequencing. Once sequences were confirmed, using M13 primers, the genes were removed 
from the vector by SgfI and PmeI enzyme restriction; these enzymes allow for cloning into 
the pFLEXI bacterial expression vector. The pFLEXI vector was used to transform KRX 
strain of competent E. coli cells which served as our expression model. SARS-CoV N, 
HCoV-NL63 N, as well as well as truncated mutants corresponding to the N- (N2) and C-
terminal (N3) of the HCoV-NL63 N protein, were included for expression. 
Transformed cells were grown in LB culture and protein expression was induced with 
the addition of rhamnose. Cultures were subsequently harvested by centrifugation and lysed 
by sonication. Protein detection was carried out by means of a Western Blot against the GST 
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affinity tag. E, M, ORF3, ORF3ΔN and MΔN HCoV-NL63 protein expression could not be 
optimally expressed as a result of several drawbacks encountered. A major one being high 
levels of background expression, which put the cells under unnecessary stress in the 
logarithmic phase of growth and thereby proving toxic to the cell. Therefore, in future 
studies, the expression conditions need to be further optimized to allow expression. 
Recommendations to improve protein expression include (1) the use of another expression 
vector system that may not prove toxic to E. coli; (2) change the GST tag to the newly used 
Halo-tag; studies have shown the latter to be more efficient in facilitating detection and 
solubility; (3) the use of Kozak sequences to initiate an effective protein translation process. 
However, the pFLEXI/KRX system proved to a good model in the expression of the HCoV-
NL63 N proteins and its truncated clones. The use of lysozymes in the lysis buffer proved 
effective in increasing protein solubility from the membrane bound cell fraction allowing the 
HCoV-NL63 N1, N2 and N3 proteins to be detected.  
These HCoV-NL63 N proteins were subsequently purified using a MagneGST™ 
purification system. Using whole blood cultures from three patients, IL-6, IL10 and IfN-γ 
cytokine levels stimulated by these recombinant N viral proteins was indentified. We found 
that the HCoV-NL63 N1, N2 and N3 proteins caused significant IL-6 levels in culture 
indicating that an inflammatory response is activated by these proteins. Therefore, the  
hypothesis that the HCoV-NL63 N protein is able to elicit an effective inflammatory response 
in a whole blood culture system was proven. The N1, N2 and N3 proteins did not stimulate a 
detectable IL-10 and IfN-γ response and thus, definitive results concerning these cytokines 
would require further study. Both the N- and C-terminal of the N protein, however, equally 
stimulated an IL-6 response, indicating the presence of several immunogenic peptides 
dispersed along the entire length of the HCoV-NL63 N-protein. It could also be indicative of 
the division of one immunogenic peptide between the N- and C-terminal. Inclusion of the 
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middle disordered region would therefore aid in characterizing the immunogenicity of the N-
protein. Future studies will include identifying the regions involved in dimerization and RNA 
binding, production of antibodies in a murine model and developing an antibody capture 
ELISA.  
Of particular interest, since the conclusion of this thesis, a new coronavirus was 
discovered in the Middle East earlier  in September 2012. Scientist first identified the new 
virus HCoV-EMC/2012 in a 60-year-old man suffering from acute pneumonia. The virus has 
since resulted in three fatalities, even though it has been shown to be closely related to 
viruses in Asian bats. This served as reminder to health authorities around the world of the 
threat posed by coronaviruses. Since the SARS epidemic in 2002, it has become evident that 
highly pathogenic coronavirus strains can still evolve and thus ongoing research is vital in 
understanding coronaviruses. 
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APPENDIX I: Vectors and Sequences 
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Figure 2: Sequence verification of the cloned HCoV-NL63-E gene in pGEM. 
Cloned genes were sequenced with M13 forward and reverse primers. M13 
primer binding sites are located up- and down-stream of the multiple cloning site 
allowing for easy sequencing (This data applies to figures 2-5). E1&2_F_rev4C 
represents the gene strand sequenced with M13 forward primers, where the E1&2_R 
represents the gene strand sequenced with M13 reverse primers. The label original is 
the sequence of the HCoV-NL E gene obtained from NCBI with accession number 
AY697421 
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Figure 3: Sequence verification of the truncated clone of HCoV-NL63 ORF3ΔN-
gene in pGEM. The first HALF_ORF3_ represents the gene strand sequenced with 
M13 reverse primers, whereas the second HALF_ORF3_R below represents the gene 
strand sequenced with M13 forward primers. NL63-ORF3 is the sequence of the 
HCoV-NL63 ORF 3gene obtained from NCBI with accession number AY697419. 
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Figure 4: Sequence verification of the truncated clone of HCoV-NL63 MΔN-gene 
in pGEM. The first HALF_M_For represents the gene strand sequenced with M13 
forward primers, whereas the second HALF_M_Rev represents the gene strand 
sequenced with M13 reverse primers. NL63-M_AY6 is the sequence of the HCoV-
NL63 M-gene obtained from NCBI with accession number AY697422 
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Figure 5: Sequence verification of the cloned full length HCoV-NL63 ORF3-gene 
in pGEM. The ORF3-5Cons represents the gene strand sequenced with M13 forward 
primers, whereas the ORF3_1Cons represents the gene strand sequenced with M13 
reverse primers. The middle sequence labelled original is the sequence of the HCoV-
NL63 ORF3-gene obtained from NCBI with accession number AY567487.2 
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APPENDIX II: Results of protein optimisation protocols using the pFLEXI vector 
system 
 
Induction at specific OD600 reading with fermentation at 37°C 
As mentioned in section 2.3.3.2 of Chapter II glycerol stocks were inoculated into 10ml of 
LB medium and incubated for 14 hours at 37°C with shaking at 180rpm. Starter cultures were 
diluted 1:100 into 100ml LB medium and incubated for approximately 4 hours when OD600 
readings were taken. Once the culture reached an OD600 of 0.3-0.4, expression was induced 
by the addition of 0.1% (w/v) rhamnose. Cultures were incubated as previously described for 
24 hours when cells were harvested by centrifugation at 6000rpm for 15min. Detection was 
carried out using SDS-page gel and Western blot. The observed molecular weights of the 
recombinant proteins appended with an N-terminal GST tag were predicted to be MΔN: 
~42kDa; ORF3ΔN: ~42kDa; M: ~72kDa; ORF3 ~72kDa and E: ~36kDa. Figure six A and B 
below represents the expression results obtained for this protocol. Expression was 
undetectable and thus we further modified the expression protocol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: (A) Coomassie stain, (B) Western Blot detection of GST fusion viral proteins. 
Lane 1: E; Lane 2: M; Lane 3: MΔN, Lane 4: ORF 3Lane 5: ORF3ΔN; Lane 6: Prestained 
molecular weight protein marker; Lane 7: uninduced control. Lane order has been maintained 
for Figure 6B. 
 
A B 
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Large scale expression  
The inability to detect protein expression and a reduced cell density a large scale culture was 
necessary to obtain an ideal concentration for protein purification. The expression protocols 
described previously was maintained where starter cultures were inoculated in 1500ml LB 
medium with the addition of 1mM IPTG on induction. A small level of protein expression 
was seen detected for the M protein (Figure 7) however; upon repetition of this protocol, 
expression was no longer detected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: HCoV-NL63 proteins by Western Blot with peroxidase labelled antibodies against 
the GST fusion protein. Lane 1: E; Lane 2: M; Lane 3: MΔN, Lane 4: ORF 3, Lane 5: 
Prestained molecular weight protein marker; Lane 6: ORF3ΔN; Lane 7: uninduced control. 
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APPENDIX III: Cloning into the pGEX-4T-2 expression vector for further studies 
using the IPTG inducible system. 
 
Cloning of the HCoV-NL63 E, M and N genes into the pGEX-4T-2 expression vector 
The pGEX-4T-2 vector was used to enable the expression of the HCoV-NL63 E, M and N 
proteins outside the scope of this thesis. Protein expression from a pGEXplasmid is under the 
control of the tac promoter, which is induced using the lactose analog isopropyl b-D-
thiogalactoside (IPTG). 
The HCoV-NL63 E, M and N genes were PCR amplified (Figures 8, 9 and 10) using pCMV 
primers (not shown). The forward and reverse primers contained an EcoR1 and BamH1 
respectively to enable ligation into the “cut”pGEX-4T-2 vector.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: PCR amplification of HCoV-NL63 E viral gene using pCMV primers. 
Lane M: 100BP marker; Lane 1-4: HCoV-NL63 E; Lane 5: Blank; Lane6: Negative 
control using all pCMV primers. 
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The pGEX-4T-2 vector was linearised by digestion with EcoR1 and BamH1 (result not 
shown) Following restriction digest, 20ul of the linearised plasmid was treated with calf 
 
 
 
Figure 9: PCR amplification of HCoV-NL63 M viral gene using pCMV primers. 
Lane M: 100BP marker; Lane 1: HCoV-NL63 M-gene; Lane 2: Blank; Lane 3&4: 
Negative control using all pCMV primers. 
 
 
Figure 10: PCR amplification of HCoV-NL63 N viral gene using pCMV primers. 
Lane M: 100BP marker; Lane 1: Blank; Lane 2, 3&7: Negative control using all pCMV 
primers; lanes 5&6 HCoV-NL63 N-gene. 
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intestinal phosphatase (CIAP) to remove the 5’ phosphates groups from the DNA. This will 
prevent he pGEX-4T-2 vector from self re-ligation. The HCoV-NL63 E, M and N genes were 
subsequently ligated BamH1 and EcoR1 digested and visualized on a 1% agarose gel to 
confirm the presence of the gene of interest (Figure 11). Thereafter 50ng of insert was ligated 
into the cut and CIAP treated pGEX-4T-2 plasmid. 10 ul of the ligation reaction was 
transformed into competent BL21 E.coli. Transformants were selected on LB/agar/ampicillin 
plates from which colonies were picked and grown in 10ml of LB cultures. The colonies 
forming units (CFU’s) were PCR screened (Figures 12, 13 and 14) for the presence of the 
correct HCoV-NL63 E, M and N inserts using the previously mentioned pCMV primers. 
Glycerol stocks were prepared if these bacterial clones for further use. To verify the cloned 
inserts were indeed present, plasmid DNA isolated was purified and sent for sequencing 
(results not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Restriction of theHCoV-NL63 E, M and N genes with EcoR1 and 
BamH1 enzymes. Lane M: 100bp marker; Lane 1: HCoV-NL63 N-gene; Lane 2: E-
gene; Lane 3: M-gene. All viral genes have an appended 5’ EcoR1 and a 3’ BamH1 
restriction site to allow for digestion with respective enzymes and subsequent ligation 
into the pGEX-4t-2 vector. 
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Figure 12: Colony PCR of BL21 competent E. coli transformed with pGEX-4T-2 
vector ligated with HCoV-NL63 E viral genes. Colony PCR was performed with 
pCMV primers and used as confirmation of successful transformation and ligation. 
Lane M: 100bp marker; Lane 1-9: E gene. 
 
 
 
Figure 13: Colony PCR of BL21 competent E. coli transformed with pGEX-4T-2 
vector ligated with HCoV-NL63 M viral genes. Colony PCR was performed with 
pCMV primers and used as confirmation of successful transformation and ligation. 
Lane M: 100bp marker; Lane 1,3-8: M gene; Lane 2: Blank. 
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Figure 14: Colony PCR of BL21 competent E. coli transformed with pGEX-4T-2 
vector ligated with HCoV-NL63 N viral genes. Colony PCR was performed with 
pCMV primers and used as confirmation of successful transformation and ligation. 
Lane M: 100bp marker; Lane 1&2:- Blank;3-8: N gene.  
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